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Abstract
Phosphatidylinositol 3-kinase (PI3K) is an important regulator of cell survival, proliferation,
activation, and migration in multiple organisms and cell types.  We have sought to determine how
PI3K may regulate T lymphocyte development, a process that entails exquisitely coordinated
phases of proliferation, differentiation, and intra-organ movement. We have generated transgenic
mice that express a PI3K gain-of-function mutant specifically in thymocytes.  The p110ABD
transgene constitutes the adaptor binding domain of the PI3K catalytic subunit and this fragment
associates with adaptor subunits in vivo.  p110ABD expression induces constitutive PI3K function,
as assessed by the activity of the downstream effector Akt.  Furthermore, p110ABD-induced PI3K
function potentiates Ca++ influx induced by sub-optimal crosslinking of the antigen receptor
(TCR) on immature thymocytes.  Enhancing PI3K activity in developing T cells results in the
specific accumulation of late-stage, mature HSAlo CD3hi thymocytes of both lineages.  The
increased numbers of mature thymocytes can be partly attributed to an improvement in positive
selection.  This is demonstrated by the ability of p110ABD to promote efficient positive selection of
transgenic AND TCR thymocytes in a background that mediates sub-optimal differentiation.  The
improvement in selection is not biased to the CD4 lineage, since CD4 lineage development is not
specifically improved in class I-restricted transgenic TCR animals expressing p110ABD.
Furthermore, the effect is specific to positive selection since immature thymocyte survival and
negative selection are unaffected by p110ABD expression.  The increased mature populations are
also partly the result of impaired thymocyte emigration.  p110ABD T cells colonize the periphery
of neonatal animals and irradiated recipients slower than do non-transgenic T cells.  The ability of
PI3K to regulate positive selection effect is probably due to enhancement of Itk-mediated Ca++
influx.  By contrast, the role of PI3K in emigration appears to be independent of known
chemotactic or adhesive factors and may instead reflect the importance of subcellular
organization for chemokine receptor signaling.
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11. Introduction
1.1  T lymphocyte development in the thymus
T lymphocytes are faced with a difficult task.  As regulators of adaptive immune responses, they
must be able to recognize foreign intrusions of many types.  Furthermore, how they recognize
foreign challenge will dictate the response mounted by the immune system.  T cells survey body
tissues via a multimeric receptor complex referred to as the T cell antigen receptor (TCR).  The
lymphocytes that regulate adaptive responses express a TCR containing α and β chains; another
population utilizing γ and δ TCR chains have a different function.  αβT cell activation occurs by
direct cell-cell contact via the interaction of the TCR with short peptide fragments presented by a
MHC heterodimer.  T cells can be functionally subdivided into two populations based upon
whether they recognize MHC molecules of either class I or II.  Class I MHC molecules present
peptide fragments derived from intracellular proteins and can thus reveal viral infections, whereas
class II molecules instead present peptides derived from extracellular sources such as dying cells
or bacteria.  TCR are expressed with coreceptor molecules that allow phenotypic discrimination
of the two functional populations.  The CD8 coreceptor recognizes MHC class I molecules and
identify T cells with lytic capabilities.  On the other hand, the CD4 coreceptor binds to MHC
class II molecules, and CD4 T cells produce growth and inflammatory cytokines when
stimulated.  These two distinct types of T cells (as well as the γδ T cells) are generated from a
common precursor cell in the thymus by a complex and rigorous program of developmental and
selective processes.
T lymphocyte development in the thymus has a number of distinct roles.  Firstly, T cells must be
able to recognize a very broad array of peptide ligands.  This diversity of TCR specificity is
2accomplished by the rearrangement of small gene fragments to generate both the α and β chains
of the TCR.  Multiple fragments are available for this process, and the joining mechanism is
inherently imprecise, allowing for a nearly infinite number of antigen specificities.  However,
because of the stochastic nature of this process, TCR capable of interacting with MHC molecules
constitute a small fraction of the TCR generated and must be selected from this pool.  Secondly,
the developing T cells must correctly match coreceptor expression and functional capabilities
with the MHC specificity of the rearranged TCR.  And third, since each T cell expresses only a
single TCR, large numbers of lymphocytes must be generated from few precursors in order to
maximize the available repertoire in the periphery.  These three goals are accomplished via a
highly choreographed developmental process that coordinates rearrangement of the TCR genes,
proliferation, and differentiation (reviewed in (1)).
Like all other haematopoietic cells, T lymphocytes derive from multipotent stem cells.  Through a
mechanism that remains vague, progenitors with T cell potential leave the adult bone marrow and
migrate to the thymus via the blood.  These initial precursors do not express a TCR or any
coreceptors (CD4 or CD8) and are thus referred to as “double negative” (DN: CD4-CD8-)
thymocytes.  These DN thymocytes can be further subdivided according to the expression of
CD44 and CD25 and to the ability to give rise to multiple lineages of haematopoietic cells.
“DN1” cells express CD44 on their surface and subsequently upregulate CD25 expression to
become “DN2,” which in turn differentiate into CD25+44lo/- DN3 cells.  Whereas earlier DN
subsets can develop into NK cells, dendritic cells, or even B cells (DN1 only), DN3 cells can only
give rise to T cells.  DN3 cells begin to rearrange the β, γ, and δ loci of the TCR, but the
mechanism that directs development of the TCRαβ versus TCRγδ lineages remains unclear (2).
Successful rearrangement of the TCRβ chain constitutes the formation of a complete gene whose
product can be expressed on the surface of the cell.  Progression from the DN3 to the DN4
3(CD25-44-) stage accompanies expression of a pre-TCR consisting of the β chain paired with a
non-polymorphic pre-TCRα (pTα) chain and the CD3 complex.  During the process of “β
selection,” further TCRβ rearrangement is prevented by allelic exclusion, the thymocytes undergo
many rounds of division, and both TCR coreceptors are upregulated.
The resultant CD4+CD8+ “double positive” (DP) thymocytes enter a quiescent state and initiate
rearrangement of the TCRα locus.  Downregulation of Bcl-2 renders the DP thymocytes sensitive
to apoptosis, and the failure to successfully rearrange a TCRα chain results in a lack of survival
stimuli; these DP cells die by neglect.  Alternatively, DP cells that can successfully rearrange a
TCRα chain present a complete TCRαβ dimer on the cell surface.  The recognition of cognate
MHC molecules on antigen presenting cells induces a survival signal referred to as positive
selection (3).  These DP cells proceed to downregulate a coreceptor to generate either CD4+ or
CD8+ single-positive (SP) thymocytes according to the specificity of TCR for MHC class I or
class II molecules (4).  Cells that appropriately match coreceptor expression and MHC specificity
exit into the periphery.
The primary function of T cell surveillance is the discrimination of “foreign” from “self.”  A
weakness of the manner by which TCR are generated is that potentially auto-reactive T cells can
be generated during thymocyte development.  Such cells could be activated by healthy tissues and
consequently induce autoimmune disease.  However, thymocyte development is exquisitely tuned
to produce a phenomenon called “central tolerance.”  The MHC molecules presented to
developing T cells within the thymus are loaded with self-peptides; if a DP thymocyte interacts
with MHC-peptide with a very high affinity it is instructed to undergo apoptosis in a process
referred to as negative selection (5).  As a consequence, only DP thymocytes with a TCR that
recognizes self-MHC but cannot be fully activated by self-peptide survive and mature, thus
4enforcing central tolerance.  Few autoreactive T cells do escape central tolerance and mature in
the thymus.  These cells are subsequently maintained in a quiescent state by peripheral tolerance
mechanisms.
Following the molding of the TCR repertoire via positive and negative selection, thymocytes
undergo a final maturation process prior to exiting to the periphery.  Aside from gross phenotypic
alterations, such as the downregulation of CD69 and HSA and the upregulation of L-selectin
(CD62L) surface expression, very little is understood about the final events of thymocyte
development.  In particular, the signals that regulate emigration of fully mature T cells to
peripheral lymphoid tissues remain largely unknown.  Mechanisms to explain thymocyte exit
have mostly fallen into two central models of active movement: chemorepulsion (or “fugetaxis”)
from thymic stromal-derived elements or chemoattraction to peripheral signals (6, 7).  A third
alternative of passive regulation, the loss of responsiveness to thymic-retention signals, has
elicited less discussion.
1.2  TCR-coupled signal transduction mechanisms in DP thymocytes
Most stages of thymocyte development are directed by the many signal transduction pathways
coupled to the preTCR and TCR complexes.  The signaling networks activated are numerous and
entail multiple overlapping specificities, functional redundancies, and feedback mechanisms.
Figure 1 depicts most of the best-characterized molecules and forward signal pathways involved
in TCR signaling in DP thymocytes.
The TCR is always expressed at the cell surface in a complex with multiple CD3 chains due to
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Figure 1. TCR signal transduction in DP thymocytes.
Shown is a simplified diagram of the major signal pathways activated by TCR ligation in
thymocytes. Black arrows represent phosphorylation or activation, inverted T’s represent inhibi-
tion, and lines with back circles indicate activation via dephosphorylation. As yet undetermined
pathways are represented with dashed arrows. Grey arrows indicate TCR-induced association.
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6the interactions of their charged transmembrane domains (8).  The TCR/CD3 complex is
composed of the TCRαβ heterodimer, CD3γε and CD3δε heterodimers, and a CD3ζ homodimer.
During the interaction of the TCR with MHC, CD4 or CD8 coreceptors are recruited to the
TCR/CD3 complex.  The Src family kinase Lck is associated with the intracellular domain of
both coreceptors, but with greater affinity for CD4 (9).  Once in the vicinity of the TCR complex,
Lck phosphorylates the CD3 chain ITAMs (immunoreceptor tyrosine-based activation motifs).
This allows the recruitment and activation of Zap70, which completes phosphorylation of the
CD3 ITAMs (10).
Heavily-phosphorylated ITAM domains recruit large “signalsome” complexes via multiple
adaptor protein components.  One of the most important of the multi-protein complexes recruited
by TCR signals is that associated with the membrane-tethered adapter LAT, including the
adaptors SLP76 and Gads, Tec family tyrosine kinases (Rlk or Itk), PLCγ1 and Vav (11).  ITAM
phosphorylation also induces Phosphatidylinositol 3-kinase recruitment to the TCR and
subsequent activation (PI3K signals are discussed in greater detail below).  PI3K induces local
accumulation of PtdIns(3,4,5)P3 (Phosphatidylinositol(3,4,5)P3), recruiting pleckstrin homology
(PH) domain-containing proteins such as Akt, Tec family members, and PLCγ1.  The association
of Tec kinases and PLCγ1 with PI3K products may contribute to the colocalization of the LAT-
associated signalsome with the TCR/CD3 complex (12).  At the TCR, Lck phosphorylates and
activates many components of the signalsome, including Tec kinases (13).
Tec kinases can activate PLCγ1, thereby inducing the generation of IP3 and DAG products which
in turn regulate Ca++ flux responses and PKC, respectively (14-16).  Calcineurin is a calcium-
dependent phosphatase that binds Ca++ to become activated.  Calcineurin subsequently
dephosphorylates NF-AT, allowing nuclear translocation and transcriptional activation (17).
7TCR-mediated activation of transcription also includes upregulation of NF-κB.  NF-κB is
normally sequestered in the cytoplasmic by the associated IκB.  IΚK phosphorylates IκB, thereby
targeting it for ubiquitylation and degradation by the proteosome.  The transcription factor NF-κB
is therefore freed to translocate to the nucleus and activate transcription.  Yet another component
of the LAT signalsome, Vav, is required for IΚK activation in thymocytes and T cells, likely via
the membrane-associated protein Card11 (18).
One of the hallmark responses to TCR triggering is the activation of Ras, which can be mediated
by the LAT-associated signalsome via two alternative pathways.  In DN thymocytes, LAT can
recruit the RasGEF Sos via the adaptor protein Grb2 (19).  But Ras activation in DP thymocytes
appears to depend instead upon the DAG- and PKC-dependent RasGRP, and Ras is therefore
induced by LAT-associated PLCγ1 activity (20, 21).  Ras activation in turn activates the
Raf/Mek/Erk cascade, positively regulating Ets transcription factors and negatively regulating
E2A (22).  Another MAPK cascade, the MKK1/MKK4/Jnk pathway, is activated by TCR
triggering of DP thymocytes.  Jnk function is regulated by Vav via the Rac-induced activation of
MKK1 (23, 24).  The p38 MAPK pathway appears to be an important TCR-induced pathway as
well, but the mechanism by which they are coupled remains unknown.  Activation of the various
MAPKs results in Fos/Jun dimerization to generate the transcriptional activator AP-1.
Ultimately, the coordinate activation of these many pathways is integrated into the activation of
distinct genetic programs by groups of transcription factors including Ets factors, AP-1, NF-AT,
and NF-κB.
81.3  The molecular basis of thymocyte selection
For the last 20 years, one of the central questions of thymocyte development has been about the
distinction between positive and negative selection.  How do DP thymocytes “know” that they
express a potentially autoreactive TCR and should therefore execute an apoptotic program?  This
question is further complicated by the nature of the signals that mediate selection: both negative
and positive selection are mediated by self-derived peptides.  Early experimental evidence
indicated that thymocyte selection is best described by a qualitative model in which the activation
of unique signal transduction pathways directs cell fate, as opposed to a quantitative model which
proposes that identical signal transduction pathways downstream of the TCR are activated during
both positive and negative selection but to different degrees (5, 25).  The picture that has emerged
more recently has integrated both of these models and suggests that signal intensity thresholds
direct activation of qualitatively different signals (26).
In vitro studies demonstrate that the fate of a DP thymocyte maturing into either the CD8+/MHC
class I- or the CD4+/MHC class II-restricted lineage is directed by the nature of the peptide
presented: antagonist peptides and even some weak agonists promote maturation whereas strong
agonists induce negative selection (27-30). Strong agonists typically bind to the TCR with a Kd of
1-90 µM and a half-life of approximately 10 seconds (31).  Minor mutations that convert these
peptides into partial agonists correlate with decreased half-lives of the MHC-peptide/TCR
complex and loss of antigen-mediated deletion in vitro (31, 32).  But how do the quantitative
differences in TCR interactions translate into different developmental outcomes?  Two models
have been proposed to answer this question, the threshold and the duration models (5).  Simply
put, the threshold model posits that weak interactions activate only a subset of the signals induced
by high-affinity interactions.  According to this scheme, signals required for positive selection
9have a lower activation threshold than the pathways that mediate negative selection.  For each
TCR/ligand interaction, signal transduction pathways that are slowly recruited to the TCR
complex may be activated only by the long-lived interactions with agonists and instruct the
thymocyte to undergo apoptosis.  On the other hand, positive selection has been shown to require
sustained interactions with stromal cells, suggesting that an ongoing TCR triggering mediates
positive selection. (33, 34).  These findings have been incorporated into a duration model, in
which high affinity interactions mediate a strong but transient signal.  Low affinity interactions
instead trigger weak but sustained signals that mediate positive selection.  To date a large number
of the signals downstream of the TCR have been implicated in positive versus negative selection
discrimination (summarized in Table 1).  How these models can be applied will be discussed
below in the context of each effector that supports either.
The generation of a number of mouse lines expressing transgenic (Tg) TCR has greatly assisted
the studies of positive and negative selection.  The original studies on agonist and antagonist
peptides mediating different selection outcomes were performed in the context of Tg TCR.  Also,
MHC class I- and class II-restricted Tg TCR that induce different selection outcomes based upon
H-2 haplotype and gender have proven especially useful for separating selective processes in
vivo.  Three such Tg TCR that will be discussed further below are the class I-restricted HY and
OT-1 TCR and the class II-restricted AND TCR.  The antigenic peptide recognized by the HY
receptor is encoded on the Y chromosome: CD8 SP thymocytes are positively selected in female
animals but negatively selected in males (35).  The OT-1 TCR recognizes a peptide derived from
chicken ovalbumin, SIINFEKL.  A number of altered peptide ligand agonists and antagonists
have been characterized for this Tg TCR (29).  The AND receptor was cloned from T cells
specific for a fragment from pigeon cytochrome C and reacts with varying affinity with class II
molecules of different haplotypes.  The development of AND Tg TCR+ CD4 SP is positively
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selected by I-Ab and I-Ek molecules but negatively selected by I-As (36).
Genetic studies in mice have demonstrated the importance of immediate, TCR-proximal signaling
events for DP differentiation.  The CD3δ chain appears to be a critical TCR/CD3 component for
initiation of positive selection signals, as mice lacking this chain exhibit decreased SP
development (37). The role of CD3δ appears to be a structural one, however, since a tailless
CD3δ transgene is capable of rescuing the knockout phenotype (37).  Furthermore, a similar
phenotype is observed in animals expressing TCRα chains with a mutation in the domain that
mediates association with CD3δ (CPM) (38).  Intriguingly, no negative selection defects have
been reported in any of these animals.  Most of the TCR-proximal adaptor molecules and tyrosine
kinases appear to be equally required for positive and negative selection, however.  Both selective
processes are completely blocked in animals deficient for Zap70 and in Lck-/- animals expressing
a Lck transgene that cannot associate with CD4 or CD8 (4, 77).  Lck at least appears to play a
dose-related role for both positive and negative selection, since catalytically inactive (dLGKR)
and active (dLGF) transgenes partially inhibit and improve positive selection, respectively (22,
39, 40).  These results have been interpreted as support for the threshold model of positive versus
negative selection.  Unfortunately, thymocytes lacking the dominant adaptors at the DP stage,
LAT and SLP76, cannot develop beyond the β-selection checkpoint (41, 42).  But groups have
begun to identify critical domains in these proteins by knock-in or transgenic expression of
various point and deletion mutants in the deficient backgrounds.  Thymocytes are capable of sub-
optimal positive selection when the Gads-interacting domain of SLP76 is deleted, but there is a
more stringent requirement for N-terminal tyrosine phosphorylation sites that mediate association
with Vav and Itk (42).  On the other hand, positive and negative selection of Tg TCR+ thymocytes
are both inhibited in mice deficient for Gads, which is typically associated with both LAT and
SLP76 in DP cells (43).  Thus TCR-proximal adaptors appear to be required for coupling the
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TCR to both positive and negative selection effector pathways.
Numerous studies demonstrate that the Ras/Erk cascade is absolutely required for positive
selection.  Early work utilizing transgenic mice expressing dominant negative forms of Ras or
Mek1 under control of the lck proximal promoter indicated that this signal cascade is essential for
positive selection but dispensable for negative selection (44-46).  Similarly, expression of a
dominant-negative form of Raf inhibits positive selection of female HY thymocytes whereas the
constitutively active, oncogenic form, vRaf, improves the positive selection of HY+ thymocytes in
male animals (47).  SP thymocytes of both CD4 and CD8 lineages are decreased by roughly 50%
in Erk-1-/- mice, as well as CD3hi thymocytes and CD69+ cells, despite normal thymus size (48).
On the other hand, positive selection is improved in mice expressing the hypermorph Erksem (49).
Scaffolding proteins are also important in the regulation of positive selection by the Erk pathway:
retroviral-mediated over-expression of Ksr (for Kinase Suppressor of Ras) inhibits positive
selection in reaggregate fetal thymic organ culture (FTOC) experiments (50).  We currently
theorize that Erk mediates positive selection through the Egr/Id3/E2A transcription factor
network.  This is suggested by observation of improved positive selection when wild-type Egr1 is
overexpressed in thymocytes (51).  Furthermore, SP development is inhibited in Egr1-/- and Id3-/-
animals and in mice overexpressing the Egr inhibitor Nab2 (52, 53, E. Tse and JAI, unpublished
results).  Id proteins are repressor partners for E2A proteins, and indeed E47-/- mice exhibit
improved positive selection of both class I- and class-II-restricted Tg TCR thymocytes (54).
Notably, the effect is dosage-dependent, as the improvement was less pronounced in E47+/-
animals, a result that can be interpreted as evidence for quantitative models of TCR signaling.
The selection-mediating genes upregulated by Erk pathway activation remain to be identified.
One of the most striking features of the genetic studies of Ras/Erk in thymocytes is the absolute
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restriction of effects to positive selection.  Negative selection is completely unperturbed in all in
vivo systems examined.  A role for this pathway in negative selection is only suggested by studies
using pharmacological inhibitors, such as Mek-specific inhibitors PD98059 and UO126.  These
studies do replicate the positive selection phenotypes of the genetically-modified systems: both
PD98059 and UO126 inhibit CD4 lineage maturation and final TCR upregulation to TCRhi in
both lineages (55).  On the other hand, some groups report inhibitor-mediated negative selection
effects (56, 57) whereas others do not (58).  It is possible that effects on negative selection are
due to nonspecific inhibition of other molecules.  Although resolution of this issue in the near
future seems unlikely, popular opinion holds that Ras signals are not involved in negative
selection.  The Ras pathway is considered to be a qualitatively distinguished signal.  The positive
selection-specific functions of Erk have been offered as evidence for the duration model of
selection in conjunction with the observations of TCRα-CPM mutant thymocytes.  Werlen et al.
observe that Erk is activated only transiently by high-affinity ligands, whereas low affinity
ligands induce a sustained Erk activity (38).  Furthermore, the sustained activity is abrogated in
TCRα-CPM cells, but transient Erk activation in response to high-affinity signals is normal.
Most studies indicate that the Raf/Mek/Erk cascade is not the only Ras-induced pathway required
for positive selection.  Thymocyte development in dnRas transgenic mice cannot be rescued by
the expression of activated Mek or Erksem transgenes (22, JAI unpublished results, see Fig 11C).
The missing effector(s) remain to be identified.  Thus far most of the other Ras-related signaling
molecules that have been identified are instead situated upstream of Ras.  For example, RasGRP
is suspected to be the dominant Ras activator in DP thymocytes because the phenotype of
RasGRP-/- animals duplicates that of dnRas mice (59, 60).
The p38 and Jnk MAPK cascades are also activated downstream of the TCR and positively
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regulate the c-Fos and c-Jun components of AP-1.  In contrast to Erk, these MAPKs may be
important in positive and/or negative selection, but experimental data has proven frustratingly
contradictory.  Thymocyte development is grossly normal in mice deficient for either of the p38-
specific MAPKKs, MKK3 or MKK6 (61, 62).  But apoptosis measurements (caspase activity and
DNA fragmentation) are decreased in the MKK6-/- cells considered to be undergoing negative
selection, TCRαβint CD69lo, in the absence of MKK6 (61).  Treatment with the p38-specific
inhibitor SB203580 enhances SP generation in both CD4 and CD8 lineages (58), but it is unclear
whether this is due to enhanced positive selection or impaired negative selection. Reducing p38
activity by expressing dominant-negative MKK6 and MKK3 transgenes can improve the positive
selection of both AND and HY Tg TCR thymocytes, but negative selection was not examined
with these Tg TCR (63).  On the other hand, SB203580 rescues DP thymocytes deleted in FTOC
by anti-CD3 treatment and in negatively-selecting HY Tg TCR male mice (58). Consistent with a
role in negative selection, over-expression of MKK6 significantly reduces the number of DP
thymocytes in FTOC and almost blocks mature SP development (58)
Jnk has also been implicated in negative selection although, unlike p38, it is not constitutively
active in DN and DP thymocytes.  Jnk is activated by the MAPKKs MKK4 and MKK7, perhaps
synergistically (64).  Transgenic mice expressing a dominant-negative MKK4 under the control
of the lck proximal promoter have normal Fas-mediated deletion of DP thymocytes despite a lack
of Jnk activity (65).  However, Jnk activation by PMA and Ionomycin remains unaltered in
dMKK4 thymocytes, suggesting that MKK4 is dispensable for induction of Jnk by the TCR (65).
Fas-mediated deletion of MKK7-/- thymocytes is also normal, although the activity of Jnk was not
assessed in the thymocytes of these mice (64).  Expression of a dominant-negative form of Jnk
(dnJnk1) provides partial protection from antigen-specific deletion of DP thymocytes in Tg TCR
mice but does not influence positive selection (66).  Jnk1-/- TH cells and splenocytes
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hyperproliferate in response to TCR ligation, but no effects have been characterized in
thymocytes (67).
The Jnk pathway may be activated in thymocytes by the Rho family member Rac, which is
activated by the GTP exchange factor Vav.  Despite having very few thymocytes, Vav-/- thymii do
contain small populations of SP thymocytes and generate mature, peripheral T cells (68, 69).
However crosses to class I- or class II-restricted Tg TCR mice reveal a severe inhibition of
positive selection (69, 70).  Vav-/- thymocytes are also more sensitive to SAG-mediated negative
selection (68) and to peptide-induced apoptosis in vitro (70).  Intriguingly, expression of a
constitutively active Rac transgene in thymocytes converts positive selection to negative
selection: L61Rac1 prevents the development of CD8 SP in female HY animals (71).  This
selection conversion requires TCR/ligand interaction, however, as class I-restricted Tg TCR
thymocytes are positively selected in L61Rac1 β2m-/- mice (71).
Ca++-dependent events, such as transcription of the Nur77 family of transcription factors, appear
to be critical for negative selection: expression of a dominant negative Nur77 transgene in Tg
TCR thymocytes inhibits antigen-dependent negative selection (72).  However over-expression in
the thymus of low levels of constitutively active calcineurin, a calcium-regulated phosphatase,
does not alter negative selection (73), although calcineurin plays an important role in the
transcriptional regulation of Nur77 (74, 75).  Calcineurin activation instead improves positive
selection (73).  Therefore, subtle alteration in Ca++ responses may have a bigger impact on
positive selection.
Genetic modification of lipid signaling molecules and effectors has also revealed a role for PtdIns
signals in the selection process, which will be discussed below.
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Table 1.  Proteins implicated in positive and/or negative selection
Protein           Genetic  modification                    Positive selection         Negative Selection    References                    
TCR
CD3δ CD3δ-/- inhibited n.e. (37)
CD3δ-/- + tailless CD3δ Tg normal n.e. (37)
TCRα-CPM mutant inhibited normal (38)
     (cannot bind CD3δ)
CD3γ CD3γ∆ITAM inhibited normal (40)
Adaptor Molecules
Cbl Cbl-/- improved (76)
Gads Gads-/- inhibited inhibited (43)
Slp76 Slp76-/- + Slp76∆224-244 Tg inhibited n.e. (42)
     (cannot bind Gads)
Slp76-/- + Slp76 Y3F Tg inhibited n.e. (42)
     (mutation of N-terminal binding sites)
Tyrosine Kinases
Zap70 Zap70-/- blocked blocked (77)
Zap70-/- + inactive ZAP-70 Tg inhibited/blocked inhibited (78)
Lck dLGKR (inactive) Tg inhibited inhibited (22, 39)
dLGF (active) Tg improved improved (22, 40)
Lck-/- + LGCA Tg blocked blocked (4)
     (cannot bind CD4/8)
Ras and MAPKs
RasGRP RasGRP-/- inhibited/blocked normal (59, 60)
Grb2 Grb2-/+ normal inhibited (79)
Ras dnRas Tg inhibited normal (45, 46)
Raf dnRaf Tg inhibited ?? (47)
vRaf (active) Tg improved ?? (47)
Mek dMek Tg inhibited normal (44, 45)
dnRas +  dMek Tg blocked normal (45)
dnRas +  actMek Tg inhibited n.e. (22)
dMek +  actMek Tg partially restored n.e. (22)
Erk Erk1-/- inhibited n.e. (48)
Erk2sem (hypersensitive) Tg improved normal (49)
dnRas + Erk2sem Tg inhibited n.e. JAI, unpublished
results;see Fig.11
Ksr Ksr retroviral over-expression inhibited n.e. (50)
MKK6 MKK6-/- normal inhibited? (61)
dnMKK6 + dnMKK3 Tg inhibited n.e. (63)
MKK6 retroviral over-expression n.e. improved (58)
Jnk dnJnk1 normal inhibited (66)
(continued)
n.e.= not examined
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Table 1.  Proteins implicated in positive and/or negative selection (cont.)
Protein           Genetic  modification                    Positive selection         Negative Selection    References
Rho family-related
Vav Vav-/- inhibited/blocked improved (68-70)
Rac L61Rac-1 (active) Tg converted to negative n.e. (71)
Ca++-related
Calcineurin Calcineurin P2b∆ (active)Tg improved normal (73)
CaMKIV/Gr CaMKIV/Gr-/- inhibited normal (80)
Nur77 dnNur77 Tg n.e. inhibited (72)
Lipid Signaling
PI3K p65PI3K (active) Tg CD4 only improved n.e. (81)
p110γ-/- CD4 only inhibited n.e. (81)
PTEN PTENflox/- inhibited inhibited (82)
SHP-1 mev (SHP-1-/-) improved improved (83, 84)
dnSHP-1 Tg improved improved (83)
Tecs Itk-/- inhibited varies (85-87)
Itk-/- Rlk-/- converted to negative inhibited (86)
Rlk Tg over-expression converted to negative n.e. (16)
Itk-/- + Rlk Tg partially rescued n.e. (16)
Transcription Factors
Egr Egr1 Tg over-expression improved n.e. (51)
Egr1-/- inhibited normal (52)
Nab2 Tg over-expression inhibited n.e. E. Tse and JAI,
     (Egr inhibitor) unpublished 
results
E2A E47-/- improved normal (54)
Id3 Id3-/- inhibited inhibited (53)
NF-κB super-inhibitory IκBα Tg inhibited normal (88)
n.e.= not examined
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1.4  Chemokines and thymocyte trafficking
The sequential stages of thymocyte development are highly coupled to the intrathymic
environment.  The thymus itself is grossly organized into a cortex and a medulla, with subcortical
zones along the periphery of the organ.  Each differentiation step is the result of an interaction
between the T cell precursor and a specialized stromal cell.  For example, positive selection is
initially induced by the interactions of DP thymocytes with epithelial cells in the cortex, whereas
medullar dendritic and CD30L+ epithelial cells mediate efficient negative selection (89).  As a
result, thymocytes are almost always moving in the thymus, constantly surveying the stromal cell
types in their vicinity.  Recently a great deal of work has shown that this process is mediated by
multiple small, soluble molecules called chemokines and their cognate G protein-coupled
receptors (GPCR).
Chemokine receptors are seven transmembrane, serpentine receptors coupled to heterotrimeric G
proteins.  Receptor activation results in the exchange of GTP for GDP by the Gα subunit and the
subsequent dissociation into Gα and Gβγ subunits, which likely mediate separable functions.
Multiple signal transduction pathways are activated downstream of these receptors in T cells,
including (but not limited to) JAK-STAT, focal adhesion kinase (FAK), MAPK, PI3K, and Ca++
influx (reviewed in (90)).  The physiological consequence of chemokine binding is the
polarization of the cell and accumulation of chemokine receptors at the leading edge, followed by
oriented cell movement (91).  Accordingly, much research has focused on the mechanism by
which these receptors direct cytoskeletal remodeling.  CXCL12 treatment of Jurkat T cells
induces the phosphorylation of several proteins associated with the cytoskeleton, FAK, Cas (Crk-
associated substrate), WASP, and Nck (92).  In fact, most of what is known about chemokine
receptors in T cells has been derived from the study of CXCL12 (SDF-1) and its receptor CXCR4
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(best known as the coreceptor for HIV infection (93)).  In the MOLT4 transformed T cell line,
CXCL12 treatment induces the rapid phosphorylation of CXCR4 by the Janus kinases JAK2 and
JAK3 (94).  JAKs appear to be important for CXCR4 signaling since the JAK-specific inhibitor
AG490 blocks cell movement and Ca++ flux responses, but these effects may be mediated by an
alternative pathway since CXCL12 induces minimal nuclear translocation of STATs (94).  JAKs
may instead be important for cytoskeletal remodeling, as AG490 treatment of a haematopoietic
progenitor cell line blocked CXCL12-induced FAK phosphorylation (95).  However, the most
prominent consequence of chemokine stimulation by far is the activation of PI3K, which will be
discussed in further detail below.
Distinct stromal cells types in the thymus express various chemokines whereas chemokine
receptor expression by thymocytes is developmentally regulated (Fig. 2) (96).  DN pro-T cells
enter the thymus via venules in the cortico-medullary junction (CMJ) and rapidly migrate across
the cortex and to subcapsular zone.  The earliest thymic immigrants express CXCR4, the receptor
for CXCL12 (97-99).  The CXCL12/CXCR4 signal appears to assist in the specific recruitment of
T precursors into the thymus, since deletion of CXCR4 induces a complete block at the DN stage
(99).  CXCR4-deficient thymocytes can enter the thymus, but remain at the CMJ, and CXCL12-/-
thymocytes likewise accumulate at the DN stage (99, 100).  Intriguingly, CXCL12 expression is
restricted to the cortex, and CXCR4 expression is downregulated on DP thymocytes undergoing
positive selection (97, 99, 100).  By contrast, DP thymocytes upregulate CCR9 expression, and its
ligand, CCL25 (TECK) is expressed throughout the thymus (97).  CCR9 appears to be completely
dispensable for thymocyte development, however, since T cells are produced normally in CCR9-/-
mice (101).
Positive selection induces the upregulation of both CCR4 and CCR7: CCR7 expression requires
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Figure 2. Chemokine and chemokine receptor expression in the thymus.
Shown are the major developmental stages of T precursors and their general location within the
thymus. The organ is divided into the outer cortex (left) and inner medulla (right); the boundary
zone is indicated by light purple, and the outermost border of the cortex, called the subcapsular
zone, is represented in light blue. The chemokine receptors and their cognate ligands are repre-
sented in matched colors: green CXCR4 CXCL12, blue CCR9 CCL25, purple CCR4 CCL22, red
CCR7 CCL19 CCL21. The chemokines are expressed either by stromal cells of epithelial origin
(EC) or by dendritic cells (DC). Arrows indicate the typical migratory path of a developing thymo-
cyte: pregenitors enter from the blood stream via venules in the cortico-medullary junction and tra-
verse to cortex to the subcapsular zone. From the subcapsular zone, cells then migrate back
across the cortex, through the medulla and then out via a venule (which also expresses CCL19).
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activation of Erk and Ca++ signals, and treatment with PMA and Ionomycin is sufficient to induce
CCR7 expression in DP thymocytes (97, 98, 102, 103).  Since the CCR4 ligand CCL22 (MDC) is
produced exclusively by epithelial cells in the medulla and at the CMJ, it is tempting to speculate
that CCR4 mediates thymocyte migration into the medulla during positive selection (104).
Furthermore, CCL22+ thymic epithelial cells are predominantly CD30L+ (102), suggesting that
CCL22 may specifically recruit thymocytes to stromal cells that can induce negative selection.
However there is little experimental evidence to support this hypothesis since negative selection
is normal in CD30-/- mice (105).  Although CCR4-/- mice have been generated, the thymic
phenotype and negative selection have not been studied in these animals (106).
As described above, there are three current theories to explain thymic exit: 2 active mechanisms,
fugetaxis and peripheral chemoattraction, and one passive mechanism, loss of thymic retention.
Potential molecular candidates in these models have focused on G protein-coupled receptors
because of the block in thymocyte emigration induced by transgenic expression of pertussis toxin
(PTX), a Gi-specific inhibitor, in thymocytes (107).  In the search for the responsible receptor,
attention has recently turned to the chemokine receptor CCR7 and the GPCR S1P1.
SP thymocytes express the chemokine receptor CCR7 following the completion of positive
selection and migrate in vitro to both of its ligands, CCL19 (ELC/MIP3ß) and CCL21 (SLC/6-
Ckine/Exodus-2) (98).  Furthermore, CCL19 is expressed in the structures by which mature cells
leave the thymus, making CCR7 an attractive candidate for active chemoattraction mechanisms
for thymic exit (102).  However thymocyte emigration is unaffected in CCR7-deficient mice and
in plt/plt mice, which lack lymphoid expression of both CCL19 and CCL21 (108-110).  In fact,
emigration is almost the only thymocyte movement that is not affected by loss of CCR7 signals.
CCR7 is expressed briefly by early thymocytes during the DN1 to DN2 transition, and CCR7-/-
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DN2 cells (CD25+44+) accumulate at the CMJ, reflecting an inability to traverse the cortex to the
subcapsular zone (111).  Some cells do manage to migrate properly and successfully develop to
the DP and SP stages.  However CCR7-/- and plt/plt SP thymocytes consequently accumulate in
the cortex because of defective migration into the medulla (112).  The medullas of CCR7-/- and
plt/plt thymii contain approximately 50% of the volume of wild-type medullas and display a
marked lack of SP cells, even when SP numbers are increased due to expression of the AND Tg
TCR (112).  Intriguingly, CCR7-null and plt/plt SP thymocytes are phenotypically normal.  Tg
TCR thymocytes also undergo successful negative selection in mutant animals, suggesting that
medullar localization is dispensable for selection and SP differentiation (112).
Recent studies of the immune-suppressant drug FTY720 have indicated that sphingoside lipid
signaling may play an important role in multiple stages of lymphocyte trafficking (113).  In vivo,
FTY720 is metabolized into a sphingosine-1-phosphate (S1P) analog capable of binding the
receptors S1P1 (edg1), S1P3 (edg3), and S1P5 (edg5).  S1P1 expression is initially induced
following positive selection and is progressively upregulated during SP thymocyte maturation
(114).  A small percentage (2-4%) of late-stage (CD62Lhi) SP thymocytes migrate in vitro in
response to S1P (114).  However, the exact role of S1P in thymic egress remains unclear: Rosen
et al. report inhibition of thymic egress by S1P1 agonists (115), but thymocyte emigration is also
impaired in mice lacking S1P1 (114, 116).
1.5  Structure and function of Class IA PI3Ks
Phosphatidylinositol 3-kinases (PI3Ks) catalyze the phosphorylation of the D3 position of inositol
head groups, generating PtdIns(3)P, PtdIns(3,4)P2, and PtdIns(3,4,5)P3.  Three classes of PI3Ks
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are defined in reference to substrate specificity as well as structure and regulation.  Class I PI3Ks
can phosphorylate PtdIns(4)P and PtdIns(4,5)P2, although the latter appears to be the preferred
substrate (117).  Class IA PI3Ks consist of catalytic subunits that interact with SH2 domain-
bearing adaptor subunits, whereas the Class IB PI3K p110γ utilizes a p101 adaptor subunit and is
stimulated by G protein βγ subunits.  While multiple Class IA subunits have been implicated in T
lymphocyte signaling, the p85α and p110α subunits are thought to largely mediate PI3K function
in T cells.
All Class IA adaptor subunits are characterized by two SH2 domains, one of which is located at
the carboxyl-terminus (Fig. 3).  The intervening “Inter-SH2” domain mediates association with
the catalytic p110 subunit.  The multiple PI3K adaptor subunits are splice isoforms of three genes
(α , β , and γ).  The p85 adaptors (α  and β) are distinguished from the other Class IA adaptor
subunits by a unique, longer amino-terminus containing a SH3 domain and two proline-rich
domains.  The p85 subunits also include a RhoGAP homology domain that may interact with
small GTPases such as Rac, but whether this domain has GAP catalytic function remains
uncertain.  The Class IB adaptor subunit shows no similarity to any known proteins or domains,
but deletion studies have suggested that association with the p110γ subunit is mediated by large
portions of both the amino- and carboxyl-termini (118).
The class IA catalytic subunits are characterized by four distinct domains.  The amino-terminus
mediates association with the adaptor subunit, and the Ras-binding domain appears to be critical
for activation (227).  The kinase domain is located at the carboxyl terminus of p110α. The
crystallographic structure of p110α has not yet been determined, but that of the related class IB
p110γ  (42% sequence identity)  has  revealed  that  the  kinase  domain is ordered into a small N-
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Figure 3. Structure of PI3K subunits and principal effectors
Black arrows indicate phosphorylation; grey arrows represent interaction partners; P = proline
rich region.
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terminal lobe and a larger C-terminal lobe that superimpose with the tyrosine kinase domain of
Src (119).  The highly-conserved and PI3K-specific PIK domain consists of anti-parallel helices
that form a central domain, a spine upon which the other domains are fastened.  Class IB p110γ is
highly identical to the class IB p110s with the notable exception of the amino terminus, which has
been implicated in association with p101 (118).
According to the classic model of class IA PI3K activation, p85 is recruited to phosphorylated
YXXM motifs via its SH2 domains, thus translocating p110 to the cell membrane (Fig. 4).
Alternatively, class IB PI3Ks associate tightly with and are activated by Gβγ subunits.  Membrane
translocation allows association with Ras, an interaction that likely activates the catalytic subunit,
and subsequent phosphorylation of membrane PtdIns (227).  PI3K metabolites serve as docking
sites for multiple cytosolic proteins.  Two domains can bind PtdIns: Pleckstrin homology (PH)
domains can associate with multiple phosphorylated PtdIns whereas FYVE motifs selectively
associate with PtdIns(3)P (120).  PH domains have been identified in over 150 proteins thus far,
but only those with a KX7-13R/KXR† motif (where X is any amino acid and † represents a
hydrophobic residue) can bind PtdIns specifically (121).  These domains can associate with
PtdIns(3,4)P2 but bind with higher affinity to PtdIns(3,4,5)P3, which is absent in resting cells:
PI3K activity thus specifically recruits these PH domain-containing proteins to the vicinity of
ligated receptors.  Membrane translocation is a hallmark feature of PI3K effector activation.
PI3K function is antagonized by two phosphatases specific for PtdIns(3,4,5)P3.  SH2-domain-
containing inositol polyphosphate 5’ phosphatase (SHIP) converts PI3K products into
PtdIns(3,4)P2, whereas phosphatase and tensin homolog (PTEN) dephosphorylates the 3’ position
to regenerate PtdIns(4,5)P3.  The antagonistic effects of these two phosphatases are required for
proper PI3K regulation, and PtdIns(3,4,5)P3 accumulate in resting cells lacking either.  This effect
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Figure 4. The prototypical model of PI3K signal transduction.
According to the standard model for PI3K activity, class I PI3K heterodimers are recruited to
ligated receptor tyrosine kinases via the SH2 domains of the adaptor subunit (shown here as
p85a). Translocation to the membrane allows the catalytic subunit to interact with Ras and to
phosphorylate PtdIns(4,5)P lipids in the inner cell membrane. PtdInsP products are also gener-
ated by class I PI3K dimers that are associated with and activated by the bg subunits of G pro-
teins coupled to serpentine receptors. The resultant local accumulation of PtdInsP recruits PH
domain-containing proteins. Once translocated to the membrane, Tec kinases are
phosphorylated by the RTK-associated Src kinases and in turn activate PLCγ, thereby inducing
Ca++ flux. PDK1 contributes to activation of Akt at PtdInsP -enriched domains. Akt phsphorylates
a variety of substrates, ultimately regulating cell cycle, transcription, and survival (the latter via Bcl
family members, FKHR, and NF-κB). Black arrows represent positive regulation, inverted T’s rep-
resent inhibtion, grey arrows indicate physical association.
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can be observed in the Jurkat T cell line, which lacks both PTEN and SHIP and exhibits
constitutive membrane association of PI3K effectors; ectopic expression of SHIP1 in Jurkats is
sufficient to increase cytosolic localization of the Akt PH domain (122, 123).  There are two
structurally-unrelated pharmacological inhibitors of PI3K, Wortmannin and Ly294002, which
both bind directly to all p110 subunits.
I.6  PI3K effectors: Akt and other AGC kinases
  
The AGC family comprises a group of serine/threonine kinases that must be phosphorylated at
two sites to become active, a threonine residue within the activation or “T” loop of the kinase
domain and a C-terminal hydrophobic motif residue that may be a serine or threonine.  Multiple
AGC kinases are regulated by PI3K activity, but the best understood is Akt (PKB).  Akt is
recruited to PtdIns(3,4,5)P3 via its amino-terminal pleckstrin-homology (PH) domain (124), and
is activated at the membrane by phosphorylation of Thr308 and Ser473 (Fig. 3).  Phosphorylation
at Thr308 is mediated by the PI3K-dependent kinase PDK1, which is itself a PH domain-
containing kinase and AGC family member (148).  PI3K products may also contribute to Akt
activation by relieving intra-molecular inhibition via altered conformation, allowing access to
Thr308.  This is suggested by the observation that PtdIns(3,4,5)P3 is still required for Akt
phosphorylation by a PDK1 mutant lacking the PH domain (∆PH-PDK1) (125).  The kinase
responsible for phosphorylation at Ser473 has been designated as “PDK2” and its identity
remains uncertain.  Recently groups have discovered that PDK1 can physically associate with the
PRK2 PIF (for PDK1-interacting fragment) domain, and this interaction induces PDK1-mediated
phosphorylation of Akt Ser473 (126).  On the other hand, Ser473 is still phosphorylated upon
activation in PDK1-/- ES cells (127).  Therefore any “PDK2” function exerted by PDK1 is
27
dispensable for PI3K-mediated Akt regulation.  Following activation at the membrane, Akt
rapidly moves to the cytosol and nucleus, where it phosphorylates a number of targets.
PI3K has been generally implicated in growth, cell cycle control, activation, and survival, and
Akt appears to be a point at which many of these effects bifurcate.  The first described Akt
substrate was GSK3, originally characterized as a regulator of glycogen metabolism but since
implicated in a wide variety of cellular processes (128).  There are over 40 putative GSK3
substrates, including a large number of transcription factors (129).  Many of these must still be
verified experimentally, and certainly cell-type and cell-context specificity must be taken into
account.  This is especially evident in the varied roles of GSK3 in apoptosis.  For example,
transfection of PC12 and Rat1 cells with a catalytically active GSK3β induces apoptosis, whereas
dominant negative forms promote survival (130).  In contrast, mice deficient in GSK3β die
during early fetal development in a manner consistent with TNF toxicity due to a loss of NF-κB
function (131).  In most pathways characterized so far, GSK3 functions as a repressor that is
inactivated by Akt-mediated phosphorylation.  The repressive capacity of GSK3 can be observed
in its phosphorylation of NF-AT, promoting cytoplasmic sequestration (132).  However, Akt has
not been confirmed as an upstream regulator of this mechanism.
The best-described role of Akt is the regulation of cell survival, which is mediated via multiple
downstream effectors in addition to GSK3.  Akt directly phosphorylates the pro-apoptotic protein
Bad in vitro and in vivo on Ser136 (133).  Bad typically exerts an apoptotic function in cells by
associating with and inhibiting anti-apoptotic Bcl-2 family members.  Ser136 phosphorylation
inactivates Bad, allowing the release (and derepression) of Bcl molecules such as Bcl-XL (133).
Expression of dominant-negative PI3K or Akt potentiates TNF-mediated killing of HeLa cells,
which can be blocked by overexpression of Bcl-XL (134).  Furthermore, Ser136 of Bad is
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essential for SCF-promoted cell survival of U2 OS (human osteosarcoma) cells (133).
Akt can also induce cell survival by the regulation of transcription.  Genetic studies of insulin
receptor/PI3K survival signaling in C. elegans identified the downstream gene DAF16, a member
of the forkhead transcription factor family (135).  There are three members of this family in
mammals, FKHR, FKHRL1, and AFX, which upregulate expression of “death” genes such as
FasL and Bim (136, 137).  Akt-mediated phosphorylation at three sites inhibits forkhead
transcriptional activity and directs nuclear export, whereupon the phosphorylated factor is bound
by 14-3-3 proteins (136, 138).
PI3K may also positively regulate survival genes by inducing activation of NF-κB via Akt-
mediated phosphorylation of IKKα.  Transfection of 293 cells with either dominant-negative
PI3K or kinase-dead Akt is sufficient to block NF-κB activation by TNF, and Akt physically
associates with IKKα in fibroblasts following PDGF stimulation (139, 140).  However the
physiological importance of this putative pathway remains to be demonstrated.  This mechanism
is dependent upon IKK family member expression, since PI3K/Akt cannot regulate NF-κB in cell
types expressing more IKKβ than IKKα (141).  Furthermore, the IKKα phosphorylation site
ascribed to Akt does not correspond to an Akt consensus site (121).  Recently an alternative
mechanism by which NF-kB can be regulated has emerged, e.g., via forkhead factors, but the
requirement for upstream Akt activity remains to be demonstrated.
As mentioned above, PDK1 is an AGC family member as well and may exert PI3K functions
independent of Akt activation.  The mechanism by which PI3K regulates PDK1 has recently
come into question.  Some groups describe activation-dependent PDK1 membrane translocation
(142, 143), whereas other studies identified a cellular fraction of PDK1 that is constitutively
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associated with the plasma membrane (144).  Since a membrane-targeted Akt (gagPKB) exerts
constitutive activity in vivo (145), there must be some amount of membrane-associated PDK1 in
resting cells.  PDK1 expressed in bacteria is fully phosphorylated and active, indicating that
PDK1 can autophosphorylate (likely in trans), and that kinase activity is activation-independent
(146).  It seems then that PDK1 function downstream of PI3K is instead regulated via its access
to substrates, e.g., by Akt membrane localization.
The p70 S6 kinase (S6K) is yet another AGC kinase regulated by PI3K, apparently via the
cooperation of Akt and PDK1.  S6K T-loop phosphorylation is mediated by PDK1 in vivo and in
vitro in a Wortmannin-resistant fashion, but maximal S6K activation requires hydrophobic motif
phosphorylation (147).  This phosphorylation appears to create a PDK1 docking site by
mimicking the structure of the PIF domain from PRK2 (148).  Hydrophobic motif Thr389
phosphorylation is sensitive to both Wortmannin and rapamycin treatment in multiple cell types
(149), suggesting a role for Akt and mTOR in S6K regulation.  Indeed, Akt directly
phosphorylates mTOR in vitro, and the mTOR-binding protein RAFT1 phosphorylates S6K at
Thr389 (150, 151).  In this manner PI3K can regulate aspects of protein synthesis.
1.7  Other mediators of PI3K function
Most members of the Tec kinase family also contain PtdIns(3,4,5)P3-specific PH domains.  There
are 5 Tec kinases expressed in the haematopoietic system of mammals.  Of these five, four
contain amino-terminal PH domains (Tec, Btk, Itk, and Bmx) that mediate PI3K-dependent
membrane translocation, whereas the last (Rlk) contains an amino-terminal cysteine-rich domain
that can be palmitoylated (152).  With the exception of Rlk, Tec kinases are activated by the
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coordinated function of both PI3K and tyrosine kinases in a surprisingly complicated fashion
(153).  At its simplest, PH domain-mediated membrane translocation recruits Tec kinases to
receptor-associated tyrosine kinases that phosphorylate and activate the Tec family member.  The
critical role of PI3K in Itk regulation is pointed out by observation that deletion of the Itk PH
domain prevents the Lck-mediated phosphorylation of Itk induced by TCR cross-linking (154).
The Tec kinases also contain SH2, SH3, and proline-rich domains that mediate both
intramolecular associations and associations with other proteins (Fig. 3).  In T cells these domains
participate in the assembly of a large “signalsome” complex: Zap70-mediated phosphorylation of
adaptors LAT and SLP76 allows the formation of a multimeric complex associated with the
membrane (see Fig. 1) (155-157).  PLCγ  is likewise recruited to the membrane via a
PtdIns(3,4,5)P3-specific PH domain and associates with the signalsome complex there (19, 158,
159).  Tec kinases subsequently phosphorylate and activate PLCγ, thereby inducing DAG and
Ca++ responses (160).
Tec kinases may also exert other, less-understood functions downstream of PI3K.  Studies of a D.
melanogaster Tec homolog have revealed a function in cytoskeletal organization, and Btk, Itk
and Tec were each shown to bind to WASP, an actin-organizing molecule (161, 162).  Tec
kinases may also regulate transcription by direct interaction with transcription factors, since
nuclear translocation upon activation has been described for both Btk and Itk as well as the PI3K-
independent Rlk (152, 163, 164).  One group showed that Btk directly phosphorylates STAT5 in
a JAK3-independent manner both in vitro and in vivo (165).  Furthermore, ectopic wild-type but
not kinase-inactive forms of human Btk could rescue STAT5A phosphorylation in Btk-/- chicken
B cells (165).
PtdIns(3,4,5)P3-specific PH domains are also found in subgroups of GTP/GDP exchange factors
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(GEFs), including those specific for the Rho family GTPases and the ARF-GTPases.  In
particular, many groups have tried to determine the relationship between the PI3K and the
RhoGEF Vav.  Vav contains a PH domain, and an early model described PtdIns(3,4,5)P3-
dependent Vav activation (166).  This finding has since been fiercely challenged, however, and
structural studies of PH domains suggest that Vav should not bind PtdIns(3,4,5)P3 (167, 168).  In
conflicting experimental reports, TCR-induced phosphorylation of Vav1 in murine primary T
cells is sensitive to Ly294002, but a Vav1 mutant with PH domain deletions is phosphorylated
normally in Jurkat T cells (169).
P-Rex1 is another GEF that has attracted attention in the context of GPCR-dependent PI3K
signaling.  The Rac GEF activity of P-Rex1 isolated from neutrophil extracts was found to be
PtdIns(3,4,5)P3-dependent (170).  P-Rex1 can associate directly with the Gβγ subunit and is
activated synergistically by PtdIns(3,4,5)P3 and Gβγ in vitro and in vivo (170).  P-Rex1 does
contain a PH domain but it is not very similar to domains with known PtdIns(3,4,5)P3 specificity.
Intriguingly, like p110γ, P-Rex1 exhibits significant basal association with the cell membrane,
and it is therefore hypothesized to function as a “coincidence” factor that mediates the extremely
rapid (as fast as 10 seconds) activation of Rac following GPCR stimulation (170).  It has also
been suggested that P-Rex1 participates in a feedback loop regulating the activity of multiple
PI3Ks in chemotactic responses.  According to this model, PI3Kγ and Gβγ cooperate to initiate
actin remodeling via P-Rex1 and Rac activation.  Rac will subsequently bind to class IA adaptor
subunits to stimulate sustained PI3K activity.  Recently the related P-Rex2 was identified,
indicating possible cell-type specificity of P-Rex usage (171).
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1.8  PI3K activation in T lymphocytes
PI3K is responsive to a variety of stimuli in T cells including stimulatory signals (CD3, CD28,
ICOS), inhibitory receptors (CTLA-4), and growth factors and cytokines (IL-2, -4, -7).  PI3K
binds directly to CD28, ICOS, and CTLA-4 via the YXXM motif located in the cytoplasmic
regions of each receptor.  Phosphorylation of the tyrosine residue in this motif, possibly by the
Src kinases Lck and Fyn, allows association with the SH2 domains of p85 (172).  Other
molecules known to activate PI3K, such as the TCR, CD4 and IL-2R, lack such sequences.
Association of these receptors with PI3K may instead be mediated by other motifs such as YVXV
and YLVL, as has been shown with hepatocyte growth factor receptor and EPOR in other cell
types (173).  Following TCR cross-linking, PI3K has been shown to associate with the TCRζ and
ε chains via co-immunoprecipitation (173); however, such biochemical techniques have proven
unreliable in T cells due to the plethora of adaptor molecules which form large complexes of
multiple proteins.  Many of the complex components do not interact directly or specifically.  For
example, TCR-interacting molecule (TRIM) contains a YXXM motif that is phosphorylated upon
activation and recruits p85α to the TCR (174).  Furthermore, many signaling molecules have
been found to be constitutively associated with glycolipid-enriched domains (GEDs or rafts)
independently of known protein-protein interactions (175).  Hence association of PI3K with the
TCR and other receptors may be direct or mediated via adaptor proteins (e.g., TRIM), rafts, or
Src family members.
PI3K is activated extremely rapidly in T cells following TCR cross-linking, even preceding
increases in intracellular Ca++ (176).  Furthermore, studies in animals expressing GFP fused to the
PH domain of Akt demonstrate that PI3K activity is maintained many hours following
TCR/MHC interaction (177).  This sustained activity is required for some TCR-induced
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processes, since addition of Ly294002 within the first 9 hours is sufficient to completely block
proliferation (177).  A role in TCR-induced PI3K-mediated proliferation has been further
supported by the study of mice with genetic modifications of PI3K signaling.  For example, T
cells of p110δD910A animals, in which a kinase-inactive form of p110δ  is knocked into the
endogenous allele, exhibit reduced proliferation in response to TCR cross-linking, only 50% that
of wild-type cells (178).  This diminished response correlates with a nearly complete loss of Akt
phosphorylation, decreases in Ca++ flux, and reduced IL-2 production.  Interestingly, defective T
cell responses in p110γ-/- animals suggest that even this GPCR-linked PI3K may play a role in T
cell activation (175).  Conversely, PI3K signaling can be potentiated by deletion of PTEN:
compared to wild-type, PTEN-deficient T cells are hyperresponsive in mixed lymphocyte
reactions, produce higher amounts of cytokines, and demonstrate increased TCR-induced Akt
kinase activity (82).
The studies of knock-out and transgenic mice also provide the best indication of which PI3K
effectors are important in TCR signaling.  Two strains of mice have been generated with ligand-
independent Akt activity via constitutive membrane targeting.  The gagPKB transgene resembles
the oncogenic v-Akt, in which Akt is fused to an N-terminal gag sequence that is myristoylated
(179).  Antigen-dependent proliferation is markedly enhanced by gagPKB expression, as is
antigen-independent viability in vitro.  Independently another group fused the Lck myristoylation
signal sequence to human Akt to generate a myrPKB mutant (180).  MyrPKB expression
improves proliferative responses of thymocytes to anti-CD3 cross-linking as well as increases and
sustains GSK3 phosphorylation (180).  PI3K-dependent regulation of GSK3 downstream of the
TCR is also indicated by reduced proliferation and IL-2 production observed in T cells expressing
a catalytically active form of GSK3β (181).  In the same report, GSK3 function in T cells is
ascribed to regulation of NF-AT, as nuclear localization of this transcription factor is increased by
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treatment with lithium, an inhibitor of GSK3 (181).
Three Tec family members are expressed in T cells, all of which are phosphorylated following
TCR cross-linking: Tec, Itk, and Rlk.  Studies of mice deficient for members of this family reveal
compensatory mechanisms that suggest usage by the TCR is largely indiscriminate.  Single
knock-out animals exhibit graded disruptions of T cell function, and significant defects are only
observed in double knock-out mice.  IL-2 production by Rlk-/- splenocytes stimulated with anti-
CD3 antibodies is half that of wild-type cells; Itk-/- splenocytes produce even less, and Rlk-/-Itk-/- T
cells produce negligible quantities (182).  Singly-deficient T cells display a surprising ability to
proliferate in response to TCR cross-linking, but doubly-deficient cells are absolutely unable to
proliferate, even in mixed lymphocyte reactions (182).  These defects were attributed to severely
impaired Ca++ flux responses consequent to delayed activation of PLCγ (182).
Most of the initial work on PI3K in T cells was based on the hypothesis that it was the principal
signal contributed by CD28-mediated costimulation.  Over the years, the literature on this subject
has proven frustratingly unclear.  Part of the difficulty lies in the experimental approaches of
early studies, which depended either upon the pharmacological inhibitors of PI3K, the specificity
of which can never be certain, and/or upon use of the Jurkat T cell line, which has defects in
PtdIns(3,4,5)P3 regulation due to deficiencies in SHIP and PTEN.  To date the only genetic
modification of PI3K that modifies CD28 function in primary T cells is the p110δD910A mutant.
Splenocytes from these animals are surprisingly competent to proliferate and produce IL2 in
response to co-ligation of CD3 and CD28 (178).  Glycolipid-enriched raft recruitment to sites of
interaction with anti-CD3 + anti-CD28-coated beads is significantly impaired, however (178).
Early studies of lipid raft involvement in TCR signaling suggested that raft mobilization is the
principal contribution of CD28-induced costimulation (183); PI3K may mediate this function of
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CD28 costimulation.
There is some evidence that PI3K can play a negative regulatory role in TCR function.
Expression of a constitutively active PI3K chimera, rCD2p110, completely abrogates NF-AT
activity in Jurkat and EL4 cells induced by CD3 cross-linking but not by phorbol myristate
acetate (PMA) plus Ionomycin (57).  This effect is not mediated by Akt or Rac, as expression of
constitutively active Akt or V12Rac does not recapitulate the inhibition (57).  Conversely,
expression of a dominant negative PI3K mutant, ∆p85, induces a small increase in basal NF-AT
activity and synergistically enhances TCR induction of NF-AT (57).  NF-AT activation by the
TCR is transient, probably due to a negative-feedback mechanism that has not been characterized.
PI3K effectors may be part of this regulation and mediate termination of NF-AT activity.  This
function of PI3K could be induced by CTLA-4, to which PI3K binds via a YVLM motif in the
cytoplasmic domain (173, 16).
PI3K activation is a hallmark of chemokine signaling in T cells as well as other cell types, as
mentioned above.  CXCL12 treatment induces the rapid and transient accumulation of
PtdIns(3,4,5)P3 in Jurkat T cells: PI3K products are detectable within 15 seconds and return to
basal levels by 5 minutes following stimulation (184).  Furthermore, SHIP-deficient thymocytes
display enhanced chemotactic responses to CXCL12 (185).  To date, chemokine-induced Akt
phosphorylation has been reported for almost all T cell chemokines, including the thymic
chemokines CXCL12, CCL19, CCL22, and CCL25 (184, 186, 187).  Chemokine-induced Akt
phosphorylation is biphasic, apparently due to the coordinated regulation of both class IA and IB
PI3Ks (184).  PI3Kγ was first implicated in CXCR4 signaling by the observed pertussis toxin-
sensitivity of Akt phosphorylation (184).  Subsequent studies in Jurkat cells using a Tet-inducible
system demonstrated that CXCL12-mediated Akt phosphorylation and chemotaxis are inhibited
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but not blocked by expression of dominant negative PI3Ks, either ∆p85 or kinase-dead p110γ
(188).  Notably, the addition of Ly294002 further inhibits chemotaxis of mutant-expressing cells,
suggesting that a complete block of chemotactic responses requires the complete inhibition of
both class IA and class IB PI3Ks.  The role of p85/p110 dimers in chemokine function is deduced
from the lipid kinase activity detected in immunoprecipitates from CXCL12-stimulated T cells,
but the kinetics of p85/p110 activation are much slower than that of PtdIns(3,4,5)P3 accumulation
(184, 189).  PtdIns(3,4,5)P3 accumulation instead correlates with the rapid activation of PI3Kγ
observed by 30 seconds following CXCL12 treatment (184).  By contrast, p85-associated kinase
activity is not maximal until 20-30 minutes, which instead matches the maximal cell polarization
observed in response to CXCL12 (189).  This suggests that class IA PI3Ks are required for
functions other than lipid kinase activity, but CXCL12-stimulated Jurkat cells do exhibit
sustained Akt phosphorylation (up to 90 minutes at high concentrations of CXCL12) that may be
p85/p110-mediated (184).  Although class IA PI3Ks are almost certainly required for the signaling
of most chemokine receptors, exactly how these heterodimers contribute to chemotactic responses
remains unclear.
1.9  PI3K and its effectors in lymphocyte development
Multiple studies have described a critical role for PI3K and its downstream effectors in B
lymphocyte development.  The mutant xid, a murine model for human immunodeficiencies, has
been mapped to mutations in the PH domain of the Tec family member Btk.  Specific disruption
of p85α imposes a block on B cell development that results in a phenotype reminiscent of that of
Btk-/- mice: reduced numbers of mature B lymphocytes and a block at the pro-B to pre-B
transition (190).  This would suggest that PI3K plays a crucial role downstream of the pre-BCR.
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On the other hand, the role of PI3K in T lymphocyte has proven more elusive.  Unlike B cell
development, thymocytes are unaffected in p85α-/- mice (190). The lack of a defect in thymocytes
may be explained by the presence of p55α and p50α isoforms that are left unchanged and appear
to compensate for the p85α deficiency in the T cell lineage; PI3K activity in p85α-/- T cells is
30% of normal, versus only 5% in B cells (190).  Disruption of all three p85a isoforms causes
neonatal lethality, but p85α55α50α-/- ES cell reconstitution of RAG2-/-  mice can generate normal
thymii as assessed by FACS analyses (191).  However, again PI3K activity js not completely
abolished in p85α55α50α-/- thymocytes but rather reduced by 70%, and p85β  expression
appeares to be upregulated (191).  p85α55α50α-/- peripheral T cells are fully competent to
proliferate in response to IL-2 treatment or to TCR cross-linking alone or with CD28, and these
responses are strongly inhibited by pretreatment with Ly294002 (191).
Whereas disruption of p85α isoforms has severe effects in knockout mice including lethality,
deletion of the p85β isoforms does not affect the viability of animals.  Thymocyte development
appears grossly normal in these mice, according to flow cytometry analyses (192).  Disruption of
p110α results in early embryonic lethality between E9.5 and E10.5 characterized by a profound
proliferative defect (193).  p110β-deficient embryos also die by E10.5, but p110γ-/- and p110δ-/-
embryos are viable (175, 194-6).  Intriguingly, p110δD910A has been construed as a dominant
negative allele since T cells from these animals exhibit greater defects than p110δ-/- T cells (178,
196).  Neither modification affects thymocyte development, however, suggesting that this
catalytic subunit is not utilized in the thymus (178, 196).
The most popular dominant negative PI3K mutant is a p85 protein lacking the inter-SH2 domain
that mediates association with p110, ∆p85.  Expression of ∆p85 in FTOC inhibits proliferation
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and/or survival of thymocyte: the number of transgene-expressing thymocytes at initiation is
roughly one third that of thymocytes transfected with an empty vector (197).  After 18 days in
FTOC, six-fold fewer thymocytes are transgene positive, indicating some possible role of PI3K in
early thymocyte development.  Despite reduced numbers, both TCRαβ and TCRγδ cells are
observed in the transgenic FTOCs as well as normal percentages of DP and SP thymocytes (197).
The role of PI3K in DN thymocytes may be downstream of IL-7R.  This is suggested since DN2
and DN3 survival is significantly impaired in IL7Rα -/- mice expressing a mutant IL-7Rα
transgene lacking the intracellular domain that mediates PI3K activation (198).  On the other
hand, p110γ-/- mice have higher percentages and numbers of DN thymocytes (81).  These DN
cells are primarily small, pre-β-selection cells and include almost no large, post-β-selection cells,
indicating that p110γ deficiency disrupts preTCR rather than IL-7R signals.  DN numbers and the
large DN3 fraction are restored to normal in p110γ-/- by the transgenic expression of p65PI3K, an
activating form of p85α that slightly increases basal PtdIns(3,4,5)P3 levels and enhances TCR-
induced PI3K activity (81, 199).
Although PI3K can regulate mature T cell survival, the importance of these mechanisms in DP
thymocytes remains unclear.  p110γ-/- mice were generated independently by two groups, and
both report slight DP decreases.  This may be due to impaired β-selection, as observed by
Rodriguez-Borlado et al., or it may be due to the increased susceptibility to GPCR-induced
apoptosis observed by Sasaki et al. (81, 175).  In vitro DP survival is enhanced for both PTEN-
deficient and gagPKB thymocytes but is largely unaffected in myrPKB mice (82, 179, 180).
Intriguingly, Dexamethasone-induced apoptosis of PTEN-deficient and p110γ-/- thymocytes is the
same as wild-type (82, 175).  DP numbers are also normal in mice from both Akt transgenic lines,
indicating that the observed changes in vitro likely do not reflect in vivo thymocyte survival
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mechanisms (179, 180).
PI3K does appear to play a role in positive selection, as neonatal p65PI3K mice have twice as many
CD3hi thymocytes as wild-type animals (81).  Whether this effect is mediated by Akt is unclear.
Whereas Jones et al. observe no change in the positive selection of Tg TCR thymocytes in
gagPKB mice, myrPKB expression improves development of such thymocytes (179, 180).
Positive selection is clearly inhibited by the loss of Tec family members, however.  Like the
graded reduction of TCR signals in these animals, the degree of inhibition correlates with the
identity of the deleted kinase: Rlk-/-Itk-/- > Itk-/- > Rlk-/-(200).  To date the positive selection of five
Tg TCR, both class I- (HY, OT-1) and class II-restricted (AND, 2B4, 5CC7), have been studied
in these mice.  Positive selection is always impaired by the loss of Tec kinases (85-87).  The
severity of the defect also correlates with the avidity of the interaction between TCR and its
selecting peptide.  For example, the selection of AND Tg TCR thymocytes was severely
compromised by Itk deficiency in the weakly-selecting H-2b background, whereas selection was
only modestly inhibited in the highly selecting H-2k background, and an intermediate effect was
observed in H-2k/b animals (87).  It should be noted, however, that the positive selection that
remains in these animals could be mediated by endogenously-rearranged TCRα chains since all
mice were Rag-competent.  Positive selection appears to be more severely compromised in Rag-/-
Itk-/- mice than Rag+/+ Itk-/- (200).  The role of Tec kinases in positive selection has also been
described in mice expressing an Rlk transgene.  In fact, Rlk over-expression can almost
completely restore positive selection of HY Itk-/- and AND Itk-/- thymocytes (16).
The effects on positive selection mediated by PI3K and Akt mutants exhibit a selective
involvement in the CD4 lineage.  CD8 SP numbers are unaffected when myrPKB is expressed in
OT-1 Tg TCR mice (180).  Surprisingly, OT-1 myrPKB animals exhibit enhanced development
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of CD4 SP thymocytes that are phenotypically mature and the spleens from these animals contain
more Tg TCR Vα2hi CD4 T cells than OT-1 littermates.  The expression of p65PI3K similarly
redirects development of thymocytes expressing the class I-restricted F5 Tg TCR into the CD8
lineage (81).  p110γ deficiency inhibits the differentiation of CD4 SP while potentiating CD8 SP
development in mice expressing the class II-restricted TCR 5CC7 (81).  These observations are in
stark contrast to those of Rlk- and Itk-deficient animals, in which lineage commitment is
unchanged (87).
Tec kinase deficiencies also reduce the efficiency of negative selection according to several
experimental models of this process.  For example, significantly increased numbers of DP and
CD8 SP thymocytes are observed in HY Tg TCR mice doubly-deficient for Rlk and Itk, and these
cells express higher levels of CD8 than those in wild-type HY animals (86). As observed for
positive selection, the inhibition of negative selection is partly dependent upon the affinity of the
TCR for the interacting ligand.  Superantigen-mediated deletion of DP thymocytes is more
severely  impaired  for  the  low-affinity 2B4 Tg TCR than for the high-affinity AND Tg  TCR  in
Itk-/- mice (200).  In view of Tec kinase-induced PLCγ function, these results agree with the
proposed role of Ca++-regulated Nur77 in negative selection.
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2.  Generation of a model system to study the molecular biology of PI3K and its role in
thymocyte development
2.1  p110ABD gain-of-function transgenic mice
Since PI3K isoform knockout animals have yielded either no effect on thymocyte development or
early embryonic lethality, we have used an alternative approach to analyze the role of PI3K at the
transition between immature DP and mature SP thymocytes.  Transgenic expression of a gain-of-
function mutant (p110ABD) allows for the modification of the pathway exclusively in developing
thymocytes, which may be important given that PI3K activity affects the survival and function of
antigen presenting cells (201-203).  We generated four lines of mice that express the p110ABD
transgene, consisting of amino acids 1-108 of the bovine Class IA catalytic subunit p110α.  This
adaptor-binding domain (ABD) mediates the association of p110α with p85 adaptor subunits.
Transgene expression is driven by the lck proximal promoter, which directs expression to
thymocytes (Fig. 5A) (204), and the 9E10 Myc epitope is included at the N-terminus for antibody
recognition.
We can easily co-immunoprecipitate p85α with p110ABD via recognition of the Myc tag by the
9E10 antibody (Fig. 5D), but we observe decreased levels of endogenous full-length p110α (Fig.
5C).  We originally expected p110ABD to exert a dominant negative effect over PI3K function: a
similar truncation mutant containing the first 126 amino acids (base pairs 1-379) was reported to
inhibit EGF-mediated expression of a reporter plasmid driven by the TPA response element
(205).  We were therefore surprised to observe constitutive activity in p110ABD thymocytes when
we assay Akt kinase activity as a surrogate readout (Fig. 6A).  We believe that p110ABD induces
PI3K activity by disrupting the normal p85-mediated regulation of endogenous p110 subunits.
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Figure 5. The p110ABD transgene product sequesters endogenous p85.
A. Diagram of the transgenic contruct utilized to generate p110ABD mice. The lck proximal pro-
moter drives transgene expression in thymocytes only. The cMyc tag sequence recognized by the
9E10 antibody was cloned at the N-terminus of the transgene, and hGH repeats allow genotyping
by PCR and dot blot.
B. Model of p110ABD function. In normal cells the adaptor p85 is bound to wild-type p110 kinase,
increasing its thermal stability but inhibiting kinase activity. In thymocytes from p110ABD
transgenic mice, the adaptor binding domain (ABD) from p110 competes with the full-length
endogenous p110 for the adaptor p85. Free p110 is catalytically active and unstable.
C. Western blot analysis to detect expression levels of wild-type, full-length p110α in thymocytes
from NLC and p110ABD transgenic mice.
D. p85α can be co-immunoprecipitated with p110ABD via the N-terminal cMyc tag of the
transgenic protein by the 9E10 antibody. Immunoprecipitations were performed upon 3 x 107
thymocytes per lane.
42
43
The mechanism by which p85 regulates catalytic subunits has proven to be far more complex
than originally suspected.  In the classical model described above in Section 1.5, adaptor subunits
function merely as scaffolding proteins that regulate the subcellular location of catalytic subunits.
That this is an oversimplification was first suggested by the observation that in vitro kinase
activity could be potentiated merely by addition of peptides containing phosphorylated YXXM
motifs (206).  When p110α is expressed in insect cells in the absence of p85α, significant lipid
kinase activity is observed (207).  Co-expression with p85α increases the amount of p110α
isolated from cell extracts but dramatically decreases kinase activity (207).  Similar results are
observed with tagged forms of p110α in HEK 293T cells.  A C-terminal Myc-tagged p110α
monomer exhibits a half-life of only 1 hour that is increased 5-fold by p85α co-expression (207).
Intriguingly, the addition of large, N-terminal GST tags could substitute for p85α co-expression
with regards to thermal stability (207).  Furthermore, kinase activity is decreased 50% by p85α
co-expression when GST-p110α is expressed in cells at 30°C, a temperature at which monomeric
GST-p110α is far more stable (207).  Deletion analysis of p85α has indicated that the N-terminal
SH2 domain mediates both inhibition of lipid kinase activity and disinhibition by
phosphopeptides (208).  These results suggest a model in which association with p85 confers
stability at 37°C but inhibits p110 lipid kinase activity.  Activation-induced translocation of the
dimer to phosphorylated sequences induces a conformational change that in turn activates lipid
kinase activity.
These results suggest that p110ABD-mediated sequestration of adaptor subunits allows endogenous
p110α to exist as an unstable monomer.  This model is depicted in Figure 5B.  Monomeric p110
subunits have constitutive lipid kinase activity, and indeed we observe the constitutive activation
of Akt, a well-known downstream effector of PI3K, in the thymocytes of mice expressing the
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p110ABD transgene.  As shown in Figure 6A by an in vitro kinase assay on Akt
immunoprecipitates, unstimulated p110ABD thymocytes display the same maximal level of Akt
activity that is induced in wild type (NLC, non-transgenic littermate control) thymocytes
following 2 minutes of stimulation with plate-bound anti-CD3, suggesting that p110ABD transgene
expression induces a physiological level of PI3K activity.
The observed decrease in Akt activity following CD3 cross-linking on the surface of p110ABD
thymocytes is intriguing, but as yet unexplained.  This suggests the activation of a TCR-
dependent, PI3K-potentiated feedback mechanism for the regulation of Akt.  Currently only two
molecules are known to negatively regulate Akt, the lipid phosphatases PTEN and SHIP.
Although both do so by depleting the cell membrane of PtdIns(3,4,5)P3, most attention has
focused on PTEN.  PTEN is expressed constitutively in the thymus but almost nothing is known
about how its activity is regulated. Preliminary studies point to internal PEST and PDZ domains
and to PI3K itself.  Whether it be PTEN or another mechanism dampening Akt activity in
p110ABD thymocytes following stimulation, it must require non-PI3K-dependent signals to be
activated.
2.2 Function of Akt effectors in p110ABD thymocytes
Various studies have shown that Akt can regulate cell survival through multiple effectors,
particularly via regulation of Bad/Bcl-XL dimerization (209, 210).  Bad contains the consensus
binding site for Akt and can be phosphorylated by Akt in vitro and in vivo (209). We examined
Bad phosphorylation in p110ABD thymocytes by immunoblotting using an anti-Bad antibody to
detect  total  unphosphorylated  and  size-shifted phosphorylated Bad as well  as  a  phospho-Bad-
Figure 6. p110ABD expression activates Akt and potentiates Ca++ flux.
A. Constitutive Akt activity is observed in resting p110ABD thymocytes. Thymocytes were stimu-
lated with 10µg/ml plate-bound anti-CD3 and in vitro kinase assays were performed with Akt
immunoprecipitates.
B. Bad phosphorylation and Bcl-X protein levels are not increased by p110ABD. Equal amounts of
protein were loaded per well for the top blots, whereas samples were titrated for Bcl-XL blotting.
The Mek antibody was used to show equivalent loading between NLC and p110ABD.
C. p110ABD does not induce increased NF- B activity, as measured by the ability to gel-shift a
radiolabeled hairpin target (shifted complex is indicated by an arrowhead).
D. S6K activation by CD3 crosslinking is not enhanced by p110ABD expression. Cells were stimu-
lated for 10 minutes on antibody-coated plates.
E. p110ABD DP thymocytes exhibit maximal Ca++ influx at lower concentrations of crosslinking
antibody than NLC DP cells. The open arrow represents the addition of 2C11 anti-CD3 at the
indicated concentration, and the black arrow indicates when the secondary crosslinker was added
(Goat-anti-Hamster, 10µg/ml).
45
L
κ
46
specific antibody.  We observed no difference in Bad phosphorylation in p110ABD thymocytes
compared to NLC (Fig. 6B).
Akt has been reported to regulate NF-κB function via direct IΚK activation in 293 cells in vivo
(211).  Additionally, an alternative mechanism for Akt-mediated IΚK activation via Cot has
recently been described.  This MAPKKK associates with Akt in 293T cells and can be directly
phosphorylated by Akt in vitro (212).  Mutation of the serine phosphorylated by Akt abrogates
Cot-mediated activation of IΚK in vitro and in vivo in 293T cells.  Importantly, this mutation also
abrogates Cot-induced NF-κB activity in Jurkat T cells (212).  Since co-expression of
constitutively active myrAkt with Cot can activate NF-κB reporter gene expression in PTEN-
competent T cells, we sought to determine if NF-κB is constitutively activated downstream of
Akt in p110ABD thymocytes.  However, when we measure NF-κB DNA-binding activity in
thymocytes by EMSA, we find that p110ABD-mediated constitutive activation of Akt is not
sufficient to activate NF-κB in resting thymocytes (Fig 6C).
Our observations that p110ABD expression does not upregulate the activity of Bcl-XL or NF-κB via
Akt is in contrast to the description of these pathways in gagPKB mice (179).  Although p110ABD
induces constitutive Akt activity, Bcl-XL levels are unaffected (Fig. 6B).  By comparison, Bcl-XL
levels are dramatically increased in resting gagPKB thymocytes.  The lack of p110ABD-induced
Bcl-XL correlates with inability of p110ABD to mediate antigen-independent Bad phosphorylation,
but Bad phosphorylation was not examined in gagPKB thymocytes.  Bad phosphorylation in
mature T cells is unaltered by gagPKB expression, however, suggesting that Akt can regulate
activity of Bcl proteins through some other mechanism that remains obscure.  Finally, it should
be noted that the difference in Akt-mediated Bcl-XL function in p110ABD and gagPKB thymocytes
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correlates with different survival capabilities, which will be discussed below.
Similarly, NF-κB activity was not examined in gagPKB thymocytes but was described to be
activated more efficiently in mature gagPKB T cells.  Given the inexact conservation of TCR-
induced signaling in thymocytes and T cells, there is a danger in extrapolating from one to the
other.  With this in mind, it is difficult to make direct comparisons between p110ABD thymocytes
and gagPKB T cells.  With regards to NF-κB regulation, however, we do have some comments.
Firstly, we did not examine TCR-induced NF-κB activity, and it is thus possible that p110ABD
may potentiate, rather than activate, NF-κB.  But we do note that Akt activity is actually
downregulated more rapidly following TCR stimulation in p110ABD thymocytes compared to
NLC, which suggests that activation-dependent enhancement is unlikely.  Secondly, to date there
is little evidence to suggest that Akt regulates NF-κB in thymocytes in vivo.  Expression cloning
from a thymus cDNA library identified a novel regulator of NF-κB, called Card11 (18).  It is
likely that NF-κB activity in thymocytes is instead regulated via a pathway associated with this
protein.
We also attempted to assess TCR-induced regulation of other putative Akt effectors, including
GSK3, FKHR, and S6K, and any effect of p110ABD upon these. Our efforts were hampered in part
by the very low levels of phosphorylation of these factors in thymocytes due to low CD3 surface
expression on DP.  We were unable to achieve reproducible TCR-phosphorylation of GSK3 or
FKHR by western blot, but did have success with detection of phospho-S6 by intracellular
staining for flow cytometry.  Although S6K regulation by PI3K and Akt has been well
documented in several systems and is important in T cells, little is known about the use of this
mechanism in thymocytes.  We find that CD3 cross-linking can induce increases in phospho-S6
levels within 10 minutes of stimulation (Fig. 6D) that are sustained at least 4 hours.  p110ABD
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expression neither increases basal phosphorylation of S6 nor potentiates TCR-induced
phosphorylation.  We suspect that S6K can only be activated in CD3hi SP thymocytes, since very
few cells upregulate S6 phosphorylation.  Simultaneous staining for surface antigens worked very
poorly but did suggest that this hypothesis is correct.
We are at a loss to explain how p110ABD-mediated constitutive Akt activity fails to induce the
biochemical changes normally observed downstream of Akt in mature lymphocytes.  This
suggests either that Akt regulation may be more complex than originally suspected or that Akt
function is not an important component of TCR signaling in thymocytes.  The first possibility
implies that the constitutively active Akt mutants used to date do not accurately represent
physiological Akt function.  The two lines of mice expressing activated Akt transgenes that have
thus far been described do report different phenotypes and biochemical effects.  Nor do the
biochemical and phenotypic characteristics of p110ABD mice match either one.  As discussed
above, gagPKB upregulates Bcl-XL whereas p110ABD does not.  On the other hand, myrPKB
induces basal Erk activity whereas p110ABD does not (shown below).  We thus conclude that
although Akt activity indicates that p110ABD functions as a gain-of-function allele for PI3K,
phenotypic alterations in p110ABD mice are likely due to Akt-independent mechanisms.
2.3  p110ABD expression potentiates Ca++ flux responses
PI3K does activate several Akt-independent pathways downstream of antigen receptors.  PH
domain-containing Tec kinases (Itk in particular) have been shown to regulate Ca++ mobilization
via PLCγ and its lipid products (73, 213).  The control of PLCγ is complex (reviewed in (214,
215)), but PI3K has been described as a positive regulator (158).  Therefore we examined the
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effects of p110ABD expression on calcium mobilization after TCR ligation.  We utilized the Ca++-
binding intracellular dye Indo-I in conjunction with fluorochrome-conjugated antibodies to CD4
and CD8 to monitor changes in intracellular calcium concentration specifically in DP thymocytes.
We compared responses of NLC and p110ABD thymocytes to CD3 cross-linking at different
concentrations.  Figure 6E shows the results of two representative experiments: expression of
p110ABD in DP thymocytes strongly potentiates Ca++ influx responses to low doses of anti-CD3,
without modifying the maximal response.  Thus constitutive activation of PI3K improves the
ability of DP to flux calcium in response to low intensity stimuli, allowing maximal Ca++ flux
responses to sub-optimal anti-CD3 antibody concentrations.  The maximal response is not
increased, suggesting that the effect of the transgene in vivo is more relevant for low affinity
TCR-MHC interactions, those that result in positive selection, than for the higher affinity
interactions involved in negative selection.
We believe that the p110ABD-mediated potentiation of Ca++ influx is due to a potentiation of Itk
activation.  This is suggested by the observation that basal levels of intracellular calcium are not
elevated in resting p110ABD thymocytes: PI3K activity does not induce Ca++ influx in the absence
of antigenic stimulation.  This correlates with the mode of Itk regulation described so far.  All PH
domain-containing Tec family kinases require the coordinate signaling of both PI3K and Src
kinases to be activated.  In T cells, PI3K activity merely induces proper subcellular localization,
whereas Lck-mediated phosphorylation activates Itk kinase function.  We propose that p110ABD-
induced PI3K activity allows constitutive association of Itk with the plasma membrane.  Thus Itk
activation by Lck is potentiated by p110ABD expression.  Unfortunately, we were unable to
examine Itk phosphorylation in thymocytes.  As can be inferred from the rapidity of Ca++ influx,
Itk is activated extremely rapidly by TCR cross-linking.  Maximal Itk phosphorylation is typically
observed by 1-2 minutes and quickly returns to basal levels following stimulation (216).
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However, we have only been able to establish reliable anti-CD3 stimulations for western blotting
with plate-bound antibodies, and this method is not amenable to such short time periods.  Despite
these limitations, we are confident that this model is correct since a complementary defect in Ca++
mobilization is observed in Itk-/- and Rlk-/-Itk-/- cells (182).  We suggest that many of the
phenotypic alterations induced by p110ABD expression are mediated by enhanced Ca++ flux
responses to TCR cross-linking.
2.4  p110ABD mice exhibit increased numbers of mature SP thymocytes
The thymii of p110ABD animals have normal cellularity but significantly increased proportions and
numbers of the more mature thymic subpopulations, e.g., CD3hi CD4 and CD8 SP thymocytes.
Figure 7A shows representative examples of transgenic and NLC thymii from the four lines of
mice, demonstrating that each of these populations are nearly doubled in p110ABD animals.  All
four lines exhibit similar phenotypes, and except where indicated, are used interchangeably
throughout this work.  We observe a slight, concomitant decrease in the DP compartment, but the
percentage of DN cells is unchanged.  When we examine the DN compartment more closely,
despite a degree of variability from animal to animal, we do not find any significant changes in
the distribution among the DN subpopulations DN1 through DN4 induced by p110ABD expression
(Fig. 7B).  Nor do we observe any p110ABD-induced change in the numbers of γ δTCR+
thymocytes.  Both αβT cell lineages are similarly increased in size, as shown by the similar
CD4:CD8 ratios observed in the CD3hi compartment of both NLC and p110ABD mice.  For the
thymii depicted in Figure 7C, these ratios are 2.91 versus 2.51, respectively.  Intriguingly, the SP
populations are enriched for cells that are more mature and express low levels of HSA (Fig. 7D).
HSA  expression  is  not  generally  disregulated  by  p110ABD,  since  DP  thymocytes  from  both
Figure 7. Phenotype of p110ABD mice.
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Figure 7. Phenotype of p110ABD mice (continued).
A. The thymii of p110ABD mice contain more SP and CD3hi cells than do NLC. Samples are
shown for all four lines generated. For the CD4/8 graphs, numbers next to each region represent
the fraction of the thymus, and bold numbers in the top right are the total number of thymocytes.
For the CD3 histograms, NLC is represented by grey fill and p110ABD by a black line. The per-
centage CD3hi is given as NLC/p110ABD.
B. DN subset distribution is unaffected by p110ABD expression. Cells from the line 15669 thymii
shown in (A) were stained for CD4, CD8, CD25, and CD44. The CD25/CD44 expression patterns
of the DN subsets are shown.
C. Both CD4 and CD8 lineage CD3hi cells are increased in p110ABD mice. The CD3 histogram is
represented as in (A). The CD4 CD8 plots represent gated CD3hi cells. NLC and p110ABD thymii
have similar ratios of CD3hi CD4:CD8 cells.
D. p110ABD mice preferentially accumulate CD3hi HSAlo cells that represent the most mature αβT
subset in the thymus. HSA expression is not generally disregulated, however, since DP cells are
still overwhelmingly HSAhi.
E. Peripheral T cells subsets are similar in NLC and p110ABD mice. The slight decreases in αβT
cells shown in p110ABD spleen represent animal-to-animal variation and are not significant. Fur-
thermore, subset representations of CD4 αβT, CD8 αβT and γδTcells are nearly identical in the
mesenteric lymph nodes of both genotypes.
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genotypes are overwhelmingly HSAhi.  The CD3hi HSAhi population varies from animal to animal:
in some mice this population represents a smaller fraction of p110ABD SP cells than of NLC (as
shown in Fig. 7D), whereas other p110ABD thymii contain more CD3hi HSAhi cells than NLC.
Any increases observed in this population in p110ABD animals are never as large as those for the
CD3hi HSAlo compartment, however.
p110ABD transgenic animals display a normal peripheral phenotype.  NLC and p110ABD mice have
similar numbers of peripheral CD4 and CD8 αβ T cells and γδ T cells in both the spleen and
mesenteric lymph nodes (Fig. 7E).  Furthermore, no transgene-induced differences are observed
in the periphery of old mice (6 months and 9 months), indicating that there is no subtle,
accumulative effect.  We also examined activation and memory markers on peripheral T cells to
see if altered thymocyte development had perturbed peripheral functions.  However, we see no
changes in the numbers of CD25+ CD69+ activated T cells or CD44hi CD62Llo memory T cells.
Clearly the levels of activity of PI3K can affect T cell development.  The accumulation of mature,
CD3hi SP thymocytes that we observe in p110ABD mice could be the result of different processes
operating at different stages of development.  At the DP stage, PI3K could modulate survival or
selection.  For example, p110ABD could improve DP survival, making it easier for the developing
cells to express a good TCR and be positively selected.  Alternatively, it could specifically
improve positively selecting signals, rescuing cells whose TCR react with very low affinity with
self MHC+peptide. On the other hand, PI3K activity could inhibit negative selection, allowing
cells that would normally be deleted to mature.  Alternatively, p110ABD may specifically modulate
SP behavior.  And a compounded effect involving more than one of these processes is also
possible.  We therefore undertook experiments to specifically investigate each of these
possibilities.  Our studies of survival and selection of DP thymocytes will be discussed in the next
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chapter, and SP thymocyte characteristics will be examined in Chapter 4.
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3.  PI3K regulates positive selection independently of negative selection and DP survival
3.1  Possible survival functions of PI3K in DP thymocytes
DP thymocytes have approximately 3 days in which to receive positive selection signals that
induce survival and maturation.  Since one of the best-characterized consequences of PI3K-
induced signals is improved cell survival, we reasoned that it may increase basal DP survival,
allowing thymocytes a longer window in which to receive selecting signals rather than directly
participating in the signal pathway of positive selection itself.
Since DP thymocytes require a strong signal to induce selection and differentiation, they display
an enhanced sensitivity to apoptotic stimuli.  This is largely due to the downregulation of Bcl-2
expression during the DN to DP transition, at which point thymocyte survival is likely mediated
by Bcl-XL (217).  Following successful positive selection, Bcl-2 expression is restored in SP
thymocytes (218).  Furthermore, forced expression of Bcl-2 in Tg TCR mice restores wild-type
numbers of DP thymocytes by sustaining non-selecting cells (219).  We therefore sought to
determine the expression pattern of Bcl-2 in p110ABD thymocytes.  When intracellular Bcl-2 levels
are measured by flow cytometry, we find that Bcl-2 expression is restricted to the DN and SP
populations of p110ABD animals, as in NLC (Fig. 8A).  We also utilized a ribonuclease-protection
assay (RPA) kit to assess the expression of multiple Bcl family members.  As shown in Figure
8B, NLC and p110ABD thymii express the same amounts of all Bcl factor mRNAs examined: pro-
apoptotic genes Bad, Bak, Bax, anti-apoptotic genes Bcl-2, Bcl-W, Bfi1, and the dual-purpose
Bcl-X are all expressed equally in NLC and p110ABD thymocytes (Fig. 8B).
Because  of  the  loss  of  Bcl-2  expression,  DP thymocytes may die due to the lack  of  antigenic
Figure 8. p110ABD expression does not alter DP survival or lifespan.
A. Bcl-2 expression is the same in NLC and p110ABD thymocytes: expression is downregulated in
DP thymocytes of both genotypes and upregulated in SP thymocytes.
B. Multiple Bcl-2 family members are expressed at the same level in NLC and p110ABD
thymocyes. An RPA kit was used in which multiple probes are used in the same sample, includ-
ing two housekeeping genes for normalization. The quantity is expressed as a fraction of GADPH
in arbitrary units.
C. p110ABD DP thymocytes are as susceptible to “death by neglect” as NLC. NLC and p110ABD
thymocytes were cultured in vitro without antigenic stimulation and survival assessed by flow
cytometry.
D. NLC and p110ABD SP thymocytes are equally susceptible to steroid-induced apoptosis.
Thymocytes were cultured with varying concentrations of Dexamethasone for 12 hours and then
analysed as in (C).
E. NLC and p110ABD DP thymocytes have the same lifespan. Since thymocyte development
exists in equilibrium, thymocytes enter the DP compartment at the same rate as which they exit
(via death or development). Therefore, when BrdU is supplied in drinking water (at 0.8 mg/ml),
thymocytes integrate BrdU as they become DP during -selection, and the average lifespan of a
DP thymocyte is the time required to completely label the compartment.
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stimulation (“death by neglect”).  They are also extremely sensitive to physiological stress or
corticosteroid exposure.  Akt activation can prevent apoptosis in multiple cell types but a similar
role for Akt in thymocytes has remained controversial.  Whereas both gagPKB and myrPKB
expression improve the viability of thymocytes treated with Dexamethasone, myrPKB has a
negligible effect on survival in the absence of stimulation (179, 180).  We thus analyzed death by
neglect by culturing thymocytes in vitro without antigenic stimulation and assessed cell survival
over time.  NLC and p110ABD DP thymocytes died at the same rate in these assays (Fig. 8C).  We
also observe identical apoptotic responses when NLC and p110ABD DP thymocytes are cultured
for 6 hours with Dexamethasone over a range of concentrations (Fig. 8D).
The survival abilities of thymocytes in vitro may not be an accurate representation of that in vivo,
however.  We therefore designed an experiment to examine DP thymocyte life span in which we
monitored the transit of thymocytes through the DP compartment using 5-bromodeoxyuridine
(BrdU).  In young animals the size of the DP compartment is in equilibrium and remains constant
through time.  Thus, cells will exit the compartment (via death or differentiation) at the same rate
as they enter it by β-selection.  By supplying animals with BrdU (0.8 mg/mL) in their drinking
water, we label thymocytes in vivo during the proliferative burst that occurs at the DN to DP
transition.  In normal animals DP thymocytes typically survive three days: therefore, after one
day of BrdU labeling, one third of the DP cells should be BrdU+ in wild-type animals.  The DP
compartments of both p110ABD and NLC mice are completely labeled at similar rates within 3-4
days (Fig. 8E), demonstrating that p110ABD and NLC DP thymocytes have the same life span.
These results are surprising since p110ABD thymocytes have increased basal Akt activity (Fig.
6A), and there is evidence that DP survival can be regulated by Bad and/or Bcl-XL via Akt.  Jones
et al. observed upregulation of Bcl-XL in gagPKB thymocytes that was presumably mediated by
58
reduced association with Bad (179).  Furthermore, overexpression of Bad in thymocytes greatly
reduces the total number of thymocytes and the percentages of SP thymocytes (220).  But in spite
of elevated Akt activity, we did not observe changes in Bad phosphorylation or Bcl-XL levels in
p110ABD thymocytes.  Nor do resting p110ABD thymocytes exhibit increased NF-κB DNA-binding
activity compared to NLC, ruling out the upregulation of survival genes controlled by this
transcription factor.  These results explain the lack of effect of p110ABD on thymocyte survival,
although we do not yet understand the compensatory mechanisms that mediate the regulation of
Bad in these cells.  However, DP survival is likewise unaffected by the expression of the
activating transgene p65PI3K (81), in agreement with our results.
This suggests that although Akt can drive DP thymocyte survival, this may not be a physiological
function of PI3K in vivo.  DP thymocytes appear to survive by a careful balance of the expression
of Bad and Bcl-XL, as apoptotic stimuli induce the upregulation of Bad expression in thymocytes
(220).  Bad is also upregulated in thymocytes after 5 hours in culture alone, although what drives
this seemingly signal-free expression is still unclear (220).  Thus it seems that Bad/Bcl-XL-
mediated regulation of DP thymocyte apoptosis occurs at the level of gene expression, rather than
via PI3K-induced post-translational events.  It should be noted that according to the RPA
analysis, in which RNA levels are measured in the same sample, more Bcl-XL was expressed than
Bad.  On the other hand, in DN thymocytes PI3K/Akt-mediated Bad phosphorylation is an
important event induced by IL-7 treatment (221).  This demonstrates that PI3K and its effectors
are utilized differently in T cells in a developmental stage-specific fashion.
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3.2  PI3K activity improves thymocyte positive selection in the Tg TCR AND system
To study if the constitutive activation of PI3K effectors could affect positive selection, we
crossed the p110ABD transgenic mice with mice bearing the Tg TCR AND (36).  This system has
been used in the past to confirm the role of Erk in positive selection (49).  The AND TCR
recognizes a fragment of pigeon cytochrome C presented by I-Ek molecules.  Thymocytes
expressing this MHC class II-restricted TCR are positively selected by I-Ab and I-Ek molecules
but not I-Ad (222).  Since the p110ABD mice were generated on a C57Bl/6 background, they are H-
2b (I-Ab I-E-).  We bred two lines of p110ABD mice to AND transgenic animals on a H-2d (I-Ad I-
Ed) background to generate progeny with a partially-selecting background, H-2b/d, in which APC
present a low amount of I-Ab that induces sub-optimal positive selection (scored as 25% CD4 SP
versus 50% in H-2b or 10% in H-2d) (49).
Expression of the p110ABD transgene significantly improves the positive selection of AND TCR-
bearing CD4 thymocytes in H-2b/d animals (Fig. 9 A).  The percentage of CD4 SP thymocytes is
increased from an average of 29.2% in AND H-2b/d mice to 41.6% in AND H-2b/d p110ABD
animals from the p110ABD 19416 line (n= 21 and 24, respectively).  Similarly, in animals from
line 15669, the CD4 SP fraction is increased from 21.8 % (n=18) to 32.5% (n=16).  As in non-Tg
TCR mice, the HSAlo compartment is especially enriched in animals expressing p110ABD.  CD4
SP HSAlo thymocytes account for only 6.3% of the thymus in AND H-2b/d mice, but they
constitute 18.1% of the thymii of AND H-2b/d p110ABD mice from line 19416.  In line 15669-
derived mice the proportions are 7.1% and 17.9%, respectively.  The total numbers of thymocytes
are decreased in AND H-2b/d p110ABD animals (19.7 ± 6.9 x 107 versus 37.5 ± 1.5 x 107), a
phenomenon that was also observed previously in AND H-2b/b Erksem animals (49).  Our results
indicate that expression of p110ABD dramatically improves AND CD4 SP selection in the H-2b/d
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Figure 9. p110ABD expression improves positive selection of AND Tg TCR thymocytes.
A. The AND Tg TCR is positively selected by I-A molecules but can not direct thymocyte devel-
opment on I-A : CD4 SP development is suboptimal in the H-2b/d background. However, expres-
sion of p110ABD increased the number of CD4 SP thymocytes in AND mice, indicating improved
positive selection.
B. 5 days following a pulse labeling of DP thymocytes, more AND H-2 p110ABD mature
thymocytes are BrdU+ than AND H-2b/d alone. This reflects more SP and CD3hi thymocytes differ-
entiating from the pool of labeled DP precursors. By contrast, if SP differentiated normally but
accumulated in p110ABD animals due to a delayed exit from the thymus, BrdU+ cells would consti-
tute a smaller fraction of SP subsets in AND p110ABD than in AND. Mice were injected twice IP
with 1mg BrdU, 3 hours apart. At five days the animals were sacrificed and cells stained for anal-
ysis by flow cytometry.
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background, almost restoring the levels observed in an optimal selecting background, H-2b/b.
However, the higher percentages of CD4 SP thymocytes observed in AND H-2b/d animals
expressing p110ABD could be due to mechanisms other than improved positive selection.  We
therefore performed BrdU pulse-chase experiments to specifically examine the generation of SP
thymocytes in the AND H-2b/d background.  Cohorts of proliferating cells are labeled with BrdU
by intra-peritoneal injection, and the thymii are analyzed by flow cytometry several days later.
The graph in Figure 9 B displays the fraction of thymocyte subpopulations that are BrdU+ 5 days
after BrdU administration.  The majority of proliferating thymocytes are those undergoing β-
selection into the DP compartment, as described above. Since the average lifespan of a DP
thymocyte is 3 days, most of the BrdU+ cells will have left the compartment by 5 days post-label,
either by selection or death by neglect.  Both AND and AND p110ABD animals have small
numbers of BrdU+ DN and DP thymocytes after 5 days.  These cells are probably the progeny of
early DN subsets that have since differentiated or even newly-arrived thymocyte progenitors.
However, a greater fraction of CD4 SP thymocytes are BrdU+ in AND p110ABD mice compared to
AND littermates.  This demonstrates that a greater fraction of the compartment is newly
generated each day, indicating improved positive selection.  In contrast, if the increased CD4 SP
populations represent thymocyte accumulation due to an exit defect, the labeled cohort should
account for a smaller fraction of the CD4 SP compartment in p110ABD animals compared to non-
transgenic littermates.  Nor can increased SP proliferation account for the higher fraction of
BrdU+ cells, as p110ABD expression does not increase SP division (discussed below in Section
4.1).  BrdU+ cells likewise account for a greater fraction of the CD3hi HSAhi and CD3hi HSAlo
populations in p110ABD-expressing mice compared to non-transgenic animals after 5 days.  BrdU
tracking thus demonstrates that improved positive selection results in greater BrdU labeling of all
mature thymocyte subsets.
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3.3  The effect of p110ABD on positive selection is lineage-independent
Recently Rodriguez-Borlado et al. published analyses of p65PI3K and p110γ -/- mice that show
affects on CD4:CD8 differentiation ratios (81).  Namely, they observe CD8 fate potentiation in
p110γ-/- neonates and a reciprocal doubling of CD4 SP in p65PI3K mice.  p110γ deficiency even
allows more development of CD8 SP thymocytes in the class II-restricted Tg TCR 5CC7 line.
On the other hand, they find that p65PI3K expression specifically impairs the development of class
I-restricted Tg TCR F5 CD8 SP thymocytes.  CD4 SP numbers are not increased in F5 p65PI3K
mice, but there are more HSA- CD4 SP compared to F5.  A role for Akt in CD4 lineage-specific
positive selection is also suggested by study of the myrPKB transgenic mice.  Na et al. find that
although expression of myrPKB does not alter SP numbers in non-Tg TCR animals, it doubles
the fraction of CD4 SP thymocytes in mice expressing the class II-restricted OT-2 Tg TCR (179).
MyrPKB can also reverse lineage choice and drive the development of CD4 SP thymocytes in
two different class I-restricted Tg TCR lines, OT-1 and HY.
By contrast, we observe no skewing of lineage choice in our p110ABD animals.  In a non-Tg TCR
background, the CD8 SP population is increased the same magnitude as the CD4 SP.  As shown
in Figure 7C, the CD4:CD8 ratio of CD3hi thymocytes in NLC and p110ABD mice is not
significantly different: 2.91 vs. 2.51 (respectively) in the animals shown.  We have crossed the
p110ABD transgene onto three different Tg TCR in total, two class I-restricted and one class II-
restricted, and we have observed no change in lineage choices.
There are significant numbers of CD8 SP thymocytes in all AND H-2b/d mice.  Some of these are
presumably the “intermediate” CD8 SP (ISP), immature cells progressing from the DN to DP
compartments that upregulate CD8 prior to CD4.  But most are CD3hi,  indicating that they are
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Figure 10. CD4 versus CD8 lineage commitment is unaltered in class I-restricted Tg TCR
p110ABD mice
A. p110ABD expression did not significantly alter the CD4:CD8 ratio of total or Vα2hi thymocytes in
OT-1 Tg TCR mice. Slight but insignificant differences were observed between two lines of
p110ABD crossed to OT-1. For line 19416, n=11 for both genotypes; for line 15669, OT-1 n=10
and OT-1 p110ABD n=9.
B. HY p110ABD female mice had very small increases in SP fractions compared to HY alone, but
the CD4:CD8 ratio was the same for both total thymocytes and Tg TCR T3.70hi thymocytes.
Representative animals are shown for each; HY n=3, HY p110ABD n=4.
63
64
mature cells that have undergone positive selection.  Since these animals were Rag+/-, these cells
may have rearranged endogenous TCRα chains and been selected by these TCR.  Or they may
simply be “mismatched,” in that coreceptor expression is not correctly matched to the MHC
specificity of the TCR, since AND Rag2-/- precursors have been shown to generate TCRhi CD8 SP
progeny (223).  Interestingly, even though p110ABD expression does not increase the percentage of
CD8 SP in AND H-2b/d animals, it does increase the BrdU+ fraction of this population in the
labeling experiments (Fig. 9B).  The increase in BrdU+ SP thymocytes is comparable between
both lineages.  This suggests that p110ABD expression can improve the positive selection of CD8
SP thymocytes even in a system biased to the CD4 fate and argues against a selective role for
PI3K in CD4 development only.
Importantly, neither do we observe an accumulation of CD4 SP thymocytes in OT-1 p110ABD
animals or in female p110ABD mice expressing the class I-restricted Tg TCR HY.  We crossed the
OT-1 Tg TCR onto two lines of p110ABD mice, 19415 and 15669.  As shown in Figure 10A, there
are no significant differences in the CD4:CD8 ratio induced by p110ABD expression.  The 19415
line demonstrates very slight increases in the ratio in p110ABD-expressing thymii, but these are
statistically insignificant.  It should also be noted that the populations expressing high levels of
the Tg TCR Vα chain, Vα2, exhibit the same CD4:CD8 ratios as for total SP thymocytes.  This is
not the case in the HY females, however (Fig. 10B).  The total SP CD4:CD8 ratios observed for
HY and HY p110ABD animals are 0.57 and 0.51 respectively (n=3 and 4).  But when only Tg TCR
T3.70hi thymocytes are analyzed, these both drop to 0.066 and 0.047.  Clearly p110ABD expression
does not specifically potentiate CD4 SP development in the MHC class I-restricted Tg TCR
systems studied.
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3.4  The roles of Ras and Erk in  p110ABD-induced positive selection
The increased positive selection in AND p110ABD animals resembles that observed in AND
transgenic animals expressing the Erk2 sevenmaker mutant (Erksem) (49).  This mutant contains a
single amino-acid substitution that mimics a mutation originally identified in D. melanogaster
genetic screens.  The substitution results in delayed dephosphorylation of Erk, and therefore the
mutant is hypersensitive to activation rather than constitutively active.  Intriguingly, Erk was one
of the first kinases shown to be inhibited in anti-CD3 stimulated T cells treated with Wortmannin
(224, 225).  PI3K-mediated Erk activation is also suggested by the impaired TCR-induced Erk
phosphorylation that is observed in p110δD910A mutant mice (178).  Furthermore, Erk is
constitutively phosphorylated in resting PTEN-deficient peripheral T cells (82).  How this
regulation could be mediated, whether via Akt or Itk, remains unclear, however.  Resting
thymocytes from myrPKB animals have higher levels of phospho-Erk than wild-type cells, and
CD3-induced Erk activation lasts significantly longer in transgenic thymocytes (180).  On the
other hand, Tec kinases may regulate Erk activity since these kinases can activate PLCγ, thereby
catalyzing the production of DAG, which in turn activates the Ras-specific GTP exchange factor
RasGRP.  Indeed, CD3-induced Erk phosphorylation is significantly impaired in Itk-/- and Rlk-/-
Itk-/- thymocytes (86).  We therefore considered the possibility that the p110ABD transgene
improves positive selection by enhancing Erk activation.
Resting thymocytes from both NLC and p110ABD mice have the same intracellular levels of
phospho-Erk when measured by flow cytometry (Fig. 11A), and both display the same sensitivity
to PMA treatment.  Unfortunately, the antibodies used for flow cytometric detection of
intracellular phospho-Erk cross-react with the 2C11 anti-CD3 antibody used for thymocyte
stimulations.   We therefore assessed CD69 expression as a representation of the Erk activity
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Figure 11. p110ABD expression does not upregulate Erk activity or restore dnRas thymo-
cyte development.
A. PMA treatment induces identical Erk phosphorylation in NLC and p110ABD thymoyctes. Fresh-
ly isolated thymocytes were stimulated with varying concentrations of PMA for 10 min and ana-
lyzed by flow cytometry.
B. CD69 expression serves as a surrogate marker for Erk activity in thymocytes, and is
upregulated at the same rate in NLC and p110ABD thymocytes. For the top graph, thymocytes
were stimulated with plate-bound anti-CD3 (10 µg/ml) and CD69 expression assessed by flow
cytometry at 3, 9, and 18 hours. The bottom graph represents CD69 expression induced by anti-
CD3 treatment for 9 hours over a range of concentrations.
C. SP and CD3hi thymocyte development is severely impaired by expression of a dominant-
negative Ras (dnRas). Neither a hypersensitive Erk (Erksem) nor p110ABD expression alone can
restore SP development. Expression of both Erksem and p110ABD does not rescue positive selec-
tion either, indicating that at least a third Ras effector pathway is required.
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induced by CD3 cross-linking, since Ras activity can direct upregulation of this marker (226).
We performed a checkerboard analysis in which thymocytes were stimulated for 3, 9, and 18
hours over a range of concentrations.  Two analyses of these experiments are shown in Figure
10B.  There are no detectable p110ABD-induced differences in the kinetics of CD69 upregulation
or in the dose response curve.  Thus although p110ABD can potentiate calcium flux responses, and
therefore concomitant DAG production, this does not activate the RasGRP/Ras/Erk pathway in
DP thymocytes.  We therefore conclude that PI3K can promote positive selection via an Erk-
independent pathway.
The Erk-independence of p110ABD-induced positive selection suggests that positive selection may
result from the integration of Erk and PI3K signals.  This is intriguing to note since defects in
positive selection induced by the expression of a dominant-negative Ras cannot be rescued by
Erksem expression (JAI, unpublished results, and Fig. 11C).  Multiple studies have suggested that
PI3K can function as a Ras effector, but this role has not been conclusively proven in
lymphocytes.  Ten years ago expression of the oncogenic vRas was shown to activate PI3K in S.
pombe and COS cells (227, 228).  Expression of a dominant negative Ras in PC12 cells is
sufficient to block PI3K activity as well, whereas expression of dominant negative PI3K (∆p85)
is sufficient to block H-RasV12-induced transformation of NIH 3T3 cells (228, 229).  The
catalytic subunits of PI3K do interact with Ras in a GTP-dependent fashion (230).  This
interaction appears to induce an activating conformational change, since a point mutation of the
critical binding residue can “mimic” Ras function and induces basal PI3K activity in COS cells
(230).  Also, p85-mediated inhibition of p110 catalytic activity may be due to prevention of p110
association with Ras (231).  However evidence suggests that PI3K does not function as a Ras
effector in T cells.  H-RasV12-induced AP-1 activity in Jurkat cells is insensitive to Ly294002
treatment at concentrations that effectively inhibit Akt activity (232).  H-RasV12 mutants have
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also been developed with mutations that restrict effector activation: PI3K is the only effector
activated by H-RasV12C40, and expression of this mutant fails to induce Ras-mediated primary
CD4 T cell activation events (145).  PI3K may be activated downstream of Ras in T cells by
chemokine receptors, however.  Transfection of H-RasV12C40 into resting peripheral T cells can
induce LFA-1 affinity changes and ICAM-1 binding normally associated with chemotactic
stimulation (233).
In light of these reports, we attempted to determine if PI3K mediated Ras effects in selection.  To
do so we used mice expressing the dominant negative mutant H-RasN17, which bears a single
amino-acid substitution within the effector loop, referred to as dnRas.  We crossed the p110ABD
transgene onto this line, but this fails to restore normal numbers of SP and CD3hi thymocytes
(Fig. 11C).  We also generated triply-transgenic mice that express dnRas, Erksem, and p110ABD, but
even these animals have decreased mature thymocyte populations.  Based on these results we
cannot be sure if PI3K functions as a Ras effector in thymocytes.  Regardless, from this we can
conclude that the Ras effector signals needed for efficient positive selection require an additional
pathway distinct from Erk and PI3K.
3.5  Negative selection is unaffected in p110ABD animals
Impaired negative selection could also contribute to the observed phenotype of p110ABD mice.
We therefore examined the potential effect of the p110ABD transgene in three model systems.  For
one, we observed deletion of p110ABD thymocytes in vivo by viral superantigens (vSAG).  All
mouse strains are endogenously infected with a variety of mouse mammary tumor viruses
(MMTVs) that express viral superantigens (vSAG) ubiquitously.  vSAG constitutively cross-link
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I-E molecules with specific TCR Vβ segments irrespective of the peptide bound by MHC (Fig.
12).  This constitutes a strong TCR signal, inducing the deletion of thymocytes bearing such
segments (234).  C57Bl/6 mice are endogenously infected with MMTV8 but do not express I-E,
and thus retain thymocytes utilizing the Vβ segments recognized by vSAG8, Vβ11 and 12.  In
addition to MMTV8, DBA/2J mice carry MMTV7, and vSAG7 recognizes Vβ6, 7, 8.1 and 9.  We
crossed the p110ABD mice on the C57BL/6 background (MMTV8+, I-E-) with DBA/2J mice
(MMTV7+ , MMTV8+, I-E+).  C57Bl/6 mice have populations of Vβ6+ and Vβ11+ SP thymocytes
(6.43% and 4.32% of SP, respectively), but in I-E+ DBA/2J x C57Bl/6 F1 mice these populations
are deleted by vSAG7 and 8 (Fig. 12A).  The p110ABD transgene does not rescue the development
of these populations in DBA/2J x C57Bl/6 F1 mice.
Superantigen-mediated deletion is an extremely stringent form of negative selection, however.  If
p110ABD exerts a subtle affect upon the signaling thresholds for selection, this effect could be
obscured in this system.  We therefore utilized an in vitro technique that allows dose-response
analysis of antigen-mediated deletion of thymocytes expressing the Tg TCR OT-1.  The OT-1
TCR recognizes an ovalbumin peptide (SIINFEKL) in the context of the MHC class I molecule
H-2Kb (29).  The co-culture of OT-1 thymocytes with antigen presenting cells (APC) presenting
SIINFEKL provides an in vitro model for negative selection that is dose-dependent (45).  OT-1
and OT-1 p110ABD thymocytes were cultured with APC loaded with different concentrations of
SIINFEKL and analyzed after 18 hours.  DP thymocytes from both OT-1 and OT-1 p110ABD are
efficiently deleted in a dose-dependent fashion, with an LD50 of 10-10M peptide.  In individual
experiments there appear to be slight increases in OT-1/p110ABD DP thymocyte survival relative
to OT-1 thymocytes at high peptide concentrations.  However, statistical analyses of the data
from multiple deletion assays (n=14), normalized so that the DP survival rate is expressed as a
percentage of the survival in the absence of peptide, shows that the difference is not significant
Figure 12. Negative selection is unaffected by p110ABD expression in vitro and in vivo.
A.The p110ABD transgene does not protect thymocytes from stringent, superantigen-mediated
negative selection. p110ABD mice (endogenously infected with MMTV8 but lacking I-E ) were
crossed with DBA/2J mice (MMTV7+ I-E+). In the F1 progeny, SAGs 7 and 8 crosslink I-E mole-
cules to TCR V 6 and V 11, respectively, efficiently inducing deletion of all thymocytes bearing
these TCR segments. Expression of p110ABD is not sufficient to rescue the development of these
thymocytes in F1 mice.
B. OT-1 and OT-1 p110ABD DP thymocytes surive the same in an in vitro deletion assay. The
p110ABD transgene was crossed onto the OT-1 transgenic line expressing a TCR specific for the
SIINFEKL peptide, and thymocytes were co-cultured for 18 hours with APCs and varying doses
of peptide. DP thymocytes will undergo antigen-dependent apoptosis with a frequency related to
the concentration of peptide. We find that although OT-1 p110ABD DP may survive slightly better
than OT-1 at high concentrations of peptide, the improvement is not significant when the data
from multiple experiments are combined. The graph includes data from 8 independent experi-
ments, each performed in duplicate (n=14 for each genotype).
C. The HY Tg TCR recognizes a male-specific peptide presented by MHC class I molecules, and
CD8 SP cells are negatively selected in male HY mice. CD8 SP and Tg TCR T3.70hi CD8 SP
cells constitute the same fraction of the thymus in HY and HY p110ABD males.
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(Fig. 12B).  This result confirms the failure of p110ABD to alter negative selection.
We also attempted to assess the effect of p110ABD expression on the deletion of HY Tg TCR
thymocytes in male animals.  Since this Tg TCR recognizes a male-specific antigen, CD8 SP
cells are efficiently deleted in male mice.  Unfortunately, we observe sizable numbers of CD8 SP
and Tg TCR T3.70hi CD8 SP thymocytes in HY males that do not express the p110ABD transgene
(Fig. 12C).  We are not certain exactly why this is but suspect it may be related to a non-specific
background effect: these mice were not backcrossed to C57Bl/6 for a full 12 generations.  HY
p110ABD males appear to have similar numbers of these thymocytes as well (Fig. 12C), but we are
reluctant to make any assertions about the effect of p110ABD expression since negative selection is
so inefficient in the control HY animals.
3.6  A model for PI3K function in thymocyte selection
We conclude that PI3K activity can specifically enhance positive selection in a lineage-
independent fashion without affecting basal DP survival or negative selection.  These results
agree most closely with the descriptions of Tec kinases in DP thymocytes.  Mice deficient for Itk
or for Itk and Rlk exhibit impaired positive selection (85-87).  However, the role of Itk in lineage
commitment remains unclear.  Itk may be more important for CD4 lineage development, since
Itk-null animals have normal numbers of peripheral CD8 T cells but reduced CD4 T cell numbers
(87).  However, CD8 SP development in class II-restricted Tg TCR backgrounds is not
potentiated by Itk deficiency as it is by loss of p110γ (81, 87).  Development of HY Tg TCR CD8
SP is inhibited in Itk-/- and Rlk-/-Itk-/- mice as well, arguing that Itk is required for positive
selection of both lineages.  Since we observe p110ABD-potentiated Ca++ flux responses to TCR
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cross-linking of DP thymocytes, we propose that PI3K-mediated activation of Itk and
downstream Ca++ responses are critical components of positive selection signals.
Whereas p110ABD expression does not modify negative selection, on the other hand Itk appears to
be an important component of this process.  The requirement for Itk for efficient negative
selection was first observed in HY Tg TCR male animals, in which the numbers of CD8 SP
thymocytes and peripheral CD8 T cells are increased in Itk-/- and Rlk-/-Itk-/- mice (85, 86).  The
same effect was observed in the CD4 lineage in a set of elegant experiments by Leslie Berg’s lab
(Lucas, et al. (200)).  They crossed Itk-/- animals expressing Tg TCR that use Vβ3 (2B4, 5CC7,
and AND) to the 129 line, in which all Vβ3+ thymocytes are deleted by endogenous SAG.  Tg
TCR thymocyte numbers are greatly reduced by SAG expression, but this reduction is less in Itk-/-
mice (200).  Specifically, SAG expression induces a 880-fold reduction in the number of DP
thymocytes in 2B4 Itk+/-  mice but only a 90-fold reduction in 2B4 Itk-/-  animals.  Lucas et al. also
examined peptide antigen-specific deletion in 5CC7 Tg TCR mice.  Inducible promoter-driven
expression of a fusion protein of hen egg lysozyme and cytochrome C (HEL-cyt) drives deletion
of 5CC7 CD4 SP thymocytes in a dose-dependent fashion (200).  Although Itk deficiency reduces
CD4 SP numbers due to impaired positive selection, HEL-cyt expression induces a smaller
decrease in the CD4 SP compartment than in Itk-competent thymii.  These experiments do
suggest a role for Itk in negative selection in vivo.
One important feature of the selection defects in Itk-/- mice is the relationship between the severity
of the effect with the avidity of the TCR/ligand interaction.  This is especially evident in the
impaired positive selection of class II-restricted Tg TCR.  When AND CD4 SP development is
assessed in Itk-/- mice on different MHC backgrounds, the defect in positive selection is most
severe in the more weakly-selecting H-2b/b background (87).  Only minor decreases are observed
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on the strongly selecting H-2k/k background, whereas Itk deficiency induces an intermediate
decrease in CD4 SP thymocytes and peripheral CD4 T cells in the mixed H-2k/b background.  Of
the Tg TCR examined in the H-2k/k background, the decrease in CD4 SP numbers induced by Itk
deficiency correlates with the avidities of TCR interactions with I-Ek: AND>5CC7>2B4 (87).
Intriguingly, the same hierarchy is observed in SAG-mediated deletion of Tg TCR thymocytes.
SAG expression induces 880- and 9-fold decreases of the numbers of DP thymocytes in 2B4 and
5CC7 mice that are Itk-competent, respectively (200). In Itk-/- mice, the decreases are only 90-
and 1.5-fold.  These results strongly indicate the existence of signaling thresholds that regulate
selection processes.
These effects appear to relate to the slower and reduced intensity TCR signaling in Itk-/-
thymocytes (87, 200).  AND Itk-/- mice accumulate CD69hi DP and SP thymocytes, suggesting
that Itk-null cells do not progress through positive selection as efficiently as cells with fully
competent Itk function (87).  Furthermore, Lucas et al. describe higher numbers of DP
thymocytes in 5CC7 and AND Tg TCR SAG+ mice that are Itk-/- versus Itk+/-, which they attribute
to delayed negative selection (200).  When CD5 expression is measured as a surrogate for TCR
signal intensity, Itk-null DP and Tg TCRhi CD4 SP thymocytes are found to express lower
amounts of CD5 (87).  Attenuated TCR signals are likely due to impaired activation of PLCγ in
Itk-/- cells (86, 235).  Itk-/- thymocytes flux Ca++ in response to TCR cross-linking as quickly as
wild-type cells to the same degree, but the sustained intracellular Ca++ concentration is
substantially lower (86).  Presumably it is this sustained increase in intracellular Ca++ levels that
mediates selection processes.
If Itk-induced Ca++ flux responses mediate negative selection, it must occur via a pathway other
than the activation of calcineurin.  Modification of calcineurin activity in thymocytes, either by
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expression of a constitutively active mutant or by knock-out of the regulatory subunit, causes
alterations of positive selection only, without changes in multiple models of negative selection
(73, 236).  Ca++-induced pathways have been implicated in negative selection before, however.
Expression of a dominant-negative Nur77 blocks negative selection in two Tg TCR models, F5
and male HY mice, but fails to alter positive selection (72, 237).  The promoter of Nur77 contains
two Ca++-responsive elements to which MEF2 can bind (74).  How Ca++ regulates Nur77
transcription remains unclear, as it may or may not involve calcineurin.  Calcineurin dependency
is suggested by sensitivity of Nur77 expression to treatment with the calcineurin inhibitor
Cyclosporin A (74).  On the other hand, Nur77 expression appears to be regulated by Ca++-
mediated antagonism of the factor Cabin1 that is insensitive another calcineurin inhibitor, FK506
(238).
Integration of these results suggests that upon TCR cross-linking in DP thymocytes, PI3K-
mediated Itk activity directs PLCγ activation and Ca++ flux.  The Ca++ response is a bifurcation
point at which positive and negative selection functions are separable: Ca++-mediated activation
of calcineurin contributes to positive selection whereas a calcineurin-independent pathway directs
negative selection, possibly via Nur77 and its homologs.  There is likely an added level of
specificity dictated by signal strength, whereby lower intensity signals drive positive selection by
activating only calcineurin.  High-avidity TCR-ligand interactions induce a higher, more
sustained Ca++ flux that allows activation of the negative selection program.  This signal threshold
model is supported by the observations of Tec kinase deficiencies in HY Tg TCR males, in which
selection is switched from negative to positive by loss of Rlk and Itk (86).  A threshold model can
also be used to explain the restriction of p110ABD effects to positive selection.  p110ABD expression
induces a modest potentiation of Ca++ signals that is sufficient to improve positive selection.  But
no significant changes to the sustained intracellular Ca++ concentration are observed in p110ABD
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mice, indicating that signal strength is not increased sufficiently to alter negative selection.
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4. A role for PI3K in thymic exit
4.1 PI3K activity in SP thymocytes
We observe that SP thymocytes of p110ABD animals exhibit a significantly higher fraction of the
most mature SP CD3hi HSAlo thymocyte population compared to NLC: 75.2% and 81.3% of CD4
SP and CD8 SP, respectively, in p110ABD versus 50.6% and 51.9% in NLC (Fig. 7D).  HSA
expression is not generally disregulated in p110ABD thymocytes, as the DP cells of both NLC and
p110ABD are overwhelmingly HSAhi (Fig. 7D).  These observations convinced us to closely
examine on the effect of p110ABD in SP thymocytes.
Newly-selected SP thymocytes are quiescent, but shortly thereafter they can proliferate.  CFSE-
labeled CD69+ SP and their progeny can undergo up to 6 cycles of division in reaggregate FTOC
experiments, but most cells divide only 1-3 times (239).  This proliferation is driven by MHC
class II+ thymic stroma, but does not require interaction with the selecting ligand since H-2d
stroma supports maturation and proliferation of H-2b thymocytes (239).  The timing of the
proliferation remains unclear, however, since BrdU labeling studies suggest instead that division
occurs immediately prior to thymic exit (240).  BrdU+ SP cells analyzed two hours after pulse
labeling are highly enriched for the most mature phenotype, HSAlo Qa-2hi (240).  When FITC is
injected intrathymically 4 hours after BrdU labeling and then peripheral organs analyzed 16 hours
later, recent thymic emigrants (FITC+) contain more BrdU+ cells than resident populations (FITC-
) (240).  From this result it is concluded that at least 10% of emigrants are just-post-cycling cells
and that 30% of the cycling SP in the thymus are ready to emigrate in the next few hours.  When
the time between BrdU and FITC injections was increased to 24 hours, Le Campion et al.
estimated that at least 50% of mature cells exiting the thymus have divided in the last 24 hours
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(241).  According to the BrdU studies, cycling SP have downregulated surface CD69 but express
varying levels of CD62L (241).
Although Akt has primarily elicited interest due to its survival-inducing effects, there is also
significant evidence to suggest that PI3K and Akt can regulate cell cycle progression and
proliferation.  One of the initial characterizations of Akt was that of the oncogenic vAkt, and the
embryonic lethality of p110α-/- mice is due to defects in proliferation rather than increased
apoptosis (193, 242).  Lymphoproliferative disorders and lymphomas are described in PTEN+/-
and p65PI3K mice (243-245).  Strikingly, myrPKB expression in an IL-2-dependent T cell
lymphoma line is sufficient to prevent G1 arrest following IL-2 withdrawal (246).  PI3K couples
the pro-mitotic function of E2F to the IL-2 receptor: expression of ∆p85 blocks IL-2-induced
activity of this transcription factor, whereas a constitutively active p110 construct induces IL-2-
independent E2F activity (247).  Furthermore, Akt can regulate multiple aspects of cell-cycle
progression via inhibition of forkhead transcription factors.  Forkhead factors are transcriptional
repressors of p27kip1 and pro-mitotic cyclins (e.g., cyclin B), and they activate the transcription of
anti-mitotic cyclins (e.g., cyclin G2) (248-250).  PI3K can also regulate translation of cyclin D
via S6K (251).  It is thus possible that PI3K and Akt can regulate cell cycle control in thymocytes
as well.
Even one additional round of proliferation would be sufficient to yield the population increases
we observe in p110ABD mice.  We therefore assessed p110ABD SP thymocyte proliferation by
measuring DNA content of CD3hi cells.  However both CD3hi HSAhi and CD3hi HSAlo populations
contain the same proportion of cells in the S/G1 phase in NLC and p110ABD animals (Fig 13A).
Intriguingly, we find that more of the earlier HSAhi cells are dividing compared to the late HSAlo
cells.   This correlates with the proposed post-selection division rather than the model of late, pre-
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Figure 13. p110ABD expression does not increase SP proliferation or alter SP thymic
localization.
A. The same fraction of NLC and p110ABD mature thymocytes are in cell cycle. DNA content
was analysed by 7AAD staining in combination with surface antigen antibodies
B. p110ABD thymii have a grossly normal thymic architecture. Discrete medullar domains are
observed in p110ABD thymii (the light blue areas), and the CMJ of NLC and p110ABD are similarly
constructed. Cryosections were stained with Giemsa and Jenners stains.
C. DP and SP thymocytes localize to cortical and medullary regions, respectively, in NLC and
p110ABD thymii. CD4 (red) and CD8 (green) SP thymocytes are found in small clusters evenly dis-
tributed throughout the medulla, whereas DP cells (yellow) are confined to the cortex. p110ABD
expression does not increase the number of cortical SP, nor do p110ABD SP accumulate at the
CMJ. Cryosections were stained with CD8-FITC and CD4-PE anitbodies and then visualized with
a laser confocal microscope.
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exit cycling.
We were also curious as to whether the alterations in p110ABD subsets correlate with disrupted
thymic architecture.  When we examine Giemsa stains of thymus sections, we find that the thymii
of transgenic and NLC animals are similarly organized into discrete cortical and medullary zones.
As shown in Figure 13B, the cortico-medullary junctions (CMJ) of p110ABD animals resemble
those of NLC.  We also find that the locations of T lineage cells are the same: SP thymocytes
complete maturation in the medulla and then return to the CMJ to exit via venules.  Dual
immunofluorescence staining with CD4 and CD8 antibodies reveals similar distributions of DP
(yellow) and SP (CD4 red, CD8 green) in both genotypes (Fig. 13C).  The medullas in p110ABD
animals appear to be more tightly packed with SP cells than NLC mice, but these cells are
relatively evenly distributed.  Importantly, clusters of p110ABD SP cells are not observed in the
cortex and do not accumulate at the CMJ.
4.2  p110ABD expression delays the appearance of peripheral T lymphocytes
In adult p110ABD mice, peripheral T numbers are the same as in NLC animals (data not shown).
However, steady-state numbers do not rule out changes in the kinetics or rate of development.
Thus we examined the thymic and peripheral phenotypes of neonatal animals.  As shown in
Figure 14A, the total thymus size increases at the same rate in both NLC and p110ABD animals.
Likewise, the accumulation of TCRβhi SP thymocytes does not occur until after the first month of
life.  However, αβ T cells appear in the spleen (Fig 14B) slower in p110ABD animals compared to
NLC.  The delay in peripheral colonization is observed in both CD4 and CD8 T cell lineages at
similar levels.  By contrast, B cell colonization of the periphery was unchanged by p110ABD
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Figure 14. Mature T lymphocytes colonize the periphery of p110ABD neonatal mice slower
than NLC.
A. Neonatal thymocytes develop at the same rate in p110ABD (open squares, dotted lines) and
NLC (closed squares, solid lines) animals. Animals were sacrificed at the times indicated, and
thymocytes stained with CD8-FITC, CD4-PE, CD3-CyChrome, and TCRβ-APC. The number of
mature CD8 SP was determined by only counting cells that were TCRβhi, thus excluding TCRβlo
ISPs. For each timepoint (n = 1 to 17).
B. Although the spleens of neonatal mice are colonized by B220+ B cells at the same rate in
NLC and p110ABD animals, the appearance of both CD4 and CD8 lineages of αβ T cells are
delayed in transgenic mice. Samples were stained with TCRγδ-FITC, B220-PE, and TCRβ-APC.
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expression.  Identical results are observed in mesenteric lymph nodes.
To verify that this difference is also present in adult thymic development rather than a
characteristic specific to fetal thymopoiesis, we devised a competitive adoptive transfer scheme to
compare the emigration kinetics of wild-type (WT) and p110ABD thymocytes.  We prepared bone
marrow cells from nontransgenic Ly5.1 Thy1.2 C57Bl/6 animals and Ly5.2 Thy1.2 p110ABD
animals.  After depleting these preparations of CD3+ T cells, we mixed cells at a 1:1 ratio and
injected 106 into lethally-irradiated Ly5.2 Thy1.1 recipients.  At subsequent timepoints of
analysis, the two transferred populations and host cells are discriminated via Ly5.1 and Thy1.1
expression (Fig. 15A, top row): wild-type cells are Ly5.1+ Thy1.1-, and p110ABD cells are Ly5.1-
Thy1.1-, whereas host cells are Ly5.1- Thy1.1+.  The efficiency of the engraftment of the two
donor populations varied from animal to animal, but within each animal we could compare the
development of B6- and p110ABD-derived lymphocytes. As shown in Figure 15A, thymic
colonization occurrs at the same rate without any reproducible accumulation of p110ABD SP  cells
compared to wild-type.  Likewise, B cells efficiently develop from precursors of both genotypes
and colonize the spleen (Fig. 15B) and mesenteric lymph nodes at the same rate.  In marked
contrast, there is a significant delay in the appearance of p110ABD-derived mature αβ T cells in the
periphery.  Wild-type T cells are readily observable by 3 weeks post-transfer, whereas p110ABD T
cells do not appear until after 6 weeks.  Even by 4 months post-transfer, the ratio of p110ABD T
cells to B cells has not reached the same value as wild type-derived cells.  It should be noted that
this imbalance in T:B ratio is observable even in animals in which the p110ABD cells engrafted
better than nontransgenic cells (see 6 week timepoint in Fig. 15B).
We believe that the eventual appearance of p110ABD-derived T cells is due to delayed but
successful thymic exit.  We do not think that these cells arise by homeostatic proliferation of a
Figure 15. p110ABD thymocyte egress is delayed relative to WT in competitive adoptive
transfers.
A. Thymic development of wild-type (Ly5.1 Thy1.2) and p110ABD (Ly5.2 Thy1.2)-derived cells is
reconstituted by 3 weeks in lethally-irradiated recipients (Ly5.2 Thy1.1).
B. Although WT-derived T cells appear in the periphery of recipient mice by 3 weeks post-
transfer, p110ABD-derived T cells do not exit the thymus until after 6 weeks. Even at 4 months, T
cells account for a smaller fraction of p110ABD-derived cells than of nontransgenic-derived cells.
82
83
very few emigrants for two reasons.  Firstly, homeostatic proliferation is induced by a paucity of
T cells in the periphery, but wild-type cells successfully fill the T cell compartment in recipient
animals prior to the appearance of p110ABD-derived T cells.  Thus any expansion of transgenic T
cells is extremely minor.  Secondly, the lck proximal promoter is downregulated following the
completion of positive selection, and mature T cells exclusively use the distal promoter.  When
transgenic mice were made using the p1017 vector driving a lacZ reporter element, both RNA
transcripts and reporter activity were undetectable in peripheral T cells (252).  Thus p110ABD-
induced PI3K activity could not contribute to the signals that drive homeostatic proliferation.
The competitive adoptive transfer experiments, in conjunction with the neonatal observations,
conclusively demonstrate an important role for PI3K in regulating the emigration of mature
thymocytes into the periphery.
The emigration defect that we observe contradicts that described in p65PI3K mice and instead
resembles that of p110γ-/- animals (81).  p65PI3K expression increases the fraction of thymically-
labeled FITC+ or BrdU+ CD4 T cells in the periphery.  The potentiation of thymic exit is restricted
to the CD4 lineage, however, as both wild-type and p65PI3K spleens contain similar numbers of
labeled CD8 T cells.  p110γ-deficiency impairs the emigration of cells from both lineages, by
contrast.  Intriguingly, p65PI3K expression in p110γ-/- mice restores thymic exit, and the numbers of
FITC+ or BrdU+ splenic T cells of both lineages are similar to those in p110γ+/- mice.  The p65PI3K-
mediated enhancement of CD4 T cell exit correlates with the enhancement of CD4 SP
differentiation, with the sum total result of fewer CD4 SP thymocytes in adult animals compared
to wild-type.  It is therefore tempting to speculate that p65PI3K expression couples the induction of
exit to the completion of positive selection.  The biochemical basis of these effects and their
differences will be discussed further below.
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4.3 Chemokine functions in p110ABD mice
The different stages of thymocyte development are very strictly correlated with specific zones
within the thymus.  Many groups have attempted to characterize the complex interplay of
chemokine and chemokine receptor expression that guide thymocyte movement from zone to
zone.  These movements are clearly regulated in part by Gα subunits, as PTX expression in the
thymus blocks migration across the CMJ and into the periphery, resulting in the accumulation of
functionally mature SP cells in the cortex (107).  The activation of PI3K molecules downstream
of GPCR has been demonstrated in multiple systems, including chemokine receptors in T
lymphocytes.  It is thus likely that the p110ABD transgene is modulating chemokine signals that
regulate thymic exit.
Despite the clear role of PTX-sensitive (and likely chemokine-mediated) signals in thymic egress,
the molecular identity of the receptors involved is not clear.  Two main candidates have been
proposed: CCR7 and S1P1.  CCR7 expression is upregulated in post-selection thymocytes by
combined Ras/Erk and Ca++ signals, and this is accompanied by the acquisition of responsiveness
to CCL19 and CCL21 in in vitro chemotaxis assays (97, 98).  However CCR7-/- mice do not have
a clear thymic exit phenotype (108).  Likewise, the spontaneous mutant “paucity of lymph node T
cells” (plt/plt), which lacks all hematopoietic CCL19 and CCL21 expression, does not display
any thymic phenotype that suggests a defect in the release of mature, naive T cells from the
thymus (109, 110, 253).  Studies of CCR7-/- and plt/plt mice suggest that CCR7 may instead be
important for proper T cell homing in the periphery.  CCR7-/- lymphocytes cannot colonize lymph
nodes efficiently upon transfer, nor can transferred wild-type cells home properly in plt/plt
animals (108, 254).  PTX transgenic thymocytes likewise fail to properly enter peripheral lymph
nodes when transferred into irradiated animals (107).  It therefore seems likely that thymocyte
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exit and peripheral lymph node entry, while both GPCR-mediated events, are distinct
mechanisms and that CCR7 is primarily used in the latter process.
More recently, attention has shifted to the S1P receptors (reviewed in (255)).  S1P1 expression
and S1P chemotactic responsiveness are also upregulated following positive selection (114, 116).
S1P1 agonist treatment induces the maturation of SP thymocytes to a CD62Lhi stage but prevents
exit from the thymus (115).  On the other hand, S1P1-/- SP thymocytes are predominantly CD62Lhi
and HSAlo but fail to fully downregulate CD69 expression, a final maturation step that appears to
be required for thymic egress since S1P1-deficient thymocytes exhibit a profound defect in
emigration (114, 116).  T cell homing to peripheral lymphoid tissues is normal, as S1P1-/-
thymocytes transferred intravenously colonize the lymph nodes and peyers patches of wild-type
host animals (114).  In view of the PTX transgenic experiments and the effects of
CCR7/CCL19/CCL21 loss, S1P1 is an attractive candidate for the regulator of thymic exit.
We assessed the expression of several developmentally-regulated GPCR in sorted CD3hi
thymocytes, to verify that our p110ABD emigration defect was not simply due to such changes.
We used quantitative real-time RT-PCR to evaluate expression of S1P1 and CCR7, which should
be restricted to late thymocytes.  Indeed, when expression is normalized to the amount in total
thymocytes, we find that both of these GPCR are highly upregulated in mature thymocyte
populations (Fig. 16A).  In agreement with the expression pattern described for S1P1, we find that
the late CD3hi HSAlo SP express the highest amounts.  On the other hand, we do not observe
increased expression at successive stages, as DP CD3hi and SP CD3hi HSAhi thymocytes express
the same relative amount of S1P1.  We also examined a receptor that is expressed at all stages of
thymocyte development, CCR9, and one that is restricted to early thymocyte subsets, CXCR4.
Again, we observe that NLC and p110ABD thymocyte subsets express roughly equivalent amounts
Figure 16. p110ABD expression does not alter chemokine receptor expression or
chemokine responses.
A. The expression levels of multiple GPCR were assessed by quantitative real-time RT-PCR.
Note that S1P1 and CCR7 are shown with a logarithmic scale. All transcripts were normalized to
GADPH expression using the formula 2-∆∆CT.
B. In vitro transwell chemotaxis assays reveal no changes in SP thymocyte responses to S1P
or CCL21.
C. Both NLC and p110ABD thymocytes slightly downregulate the integrins α4, β1, and β4 during
maturation.
D. Total thymocyte suspensions from NLC and p110ABD mice were analysed for their ability to
bind to Retronectin in vitro. Adhesion was quantitated by staining with crystal violet and measur-
ing the absorbance at 595 nM. When purified TCRβ+ HSAlo thymocytes were used, the number
of bound cells was below the level of reproducible detection (<0.2 OD).
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of these mRNAs (Fig. 16A).  Although there appears to be some alteration in the pattern of CCR9
expression, the changes are less than two-fold (note that the Y axes of the CCR9 and CXCR4
graphs are linear, whereas the S1P1 and CCR7 axes are logarithmic).  We conclude that any
modulation of chemokine responses by p110ABD is mediated by altered signal transduction
mechanisms rather than by altered expression.
We also attempted to assess any potential changes in the chemotactic responses to possible
emigration factors, namely via S1P1 and CCR7.  NLC and p110ABD thymocytes were subjected to
transwell chemotaxis assays using S1P or CCL21 as a chemoattractant.  The phenotype and
number of responding cells was assessed by flow cytometry.  The migrants in these assays are
preferentially enriched for SP thymocytes as expected, and the % of input that we measured fit in
the ranges previously described.  However we were unable to detect any reproducible difference
between NLC and p110ABD responses.  One experiment of three is shown in Figure 15B:
unfortunately, all three experiments gave sufficiently different results to make statistical analysis
fruitless.  When each experiment is examined independently, we observe no significant change
induced by p110ABD expression.  This can be seen in the very minor differences depicted in Figure
16B.  This suggests that these GPCR are insensitive to alterations in PI3K activity, and that PI3K
instead mediates the functions of some other regulator of thymocyte egress.
4.4  Integrin expression and function is unaltered by p110ABD expression
The lack of a correlation between our exit phenotype and the chemotactic responses to known
egress candidates suggests that some other, as-yet unidentified GPCR is important in this process.
We therefore examined some of the phenotypic and functional consequences of chemokine
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signaling.  One of the most striking responses to chemokine treatment is the upregulation of
integrin function.  This can be observed in the ability of CCL21 to induce lymphocyte arrest on
ICAM-1-coated surfaces under flow conditions (256).  Integrins are heterodimeric receptors
composed of α  and β  subunits, of which there are several that dimerize in a variety of
combinations.  Importantly, integrin function can be enhanced by both antigenic and chemotactic
activation via two distinct “inside-out” mechanisms (reviewed in (257)).  The first of these is a
conformational change in the extracellular domain that increases affinity for ligand.  Secondly,
the avidity of integrin binding can be enhanced by changes in lateral mobility.  PI3K signaling
appears to be important for the latter form of integrin activation in lymphocytes.  For example, β1
integrin-mediated cell adhesion can be enhanced by TCR signaling in a manner that is sensitive to
PI3K inhibitors (258).  CD3-induced increases of T cell binding to the β1 ligand fibronectin are
also inhibited by the expression of kinase-dead Itk mutants (259).  In cells expressing a
membrane-targeted Itk that constitutively localizes to glycolipid-enriched rafts, CD4 cross-
linking is sufficient to increase β1 integrin activation independently of TCR signaling (259).  It
has been suggested that Itk recruitment to these rafts allows subsequent cytoskeletal remodeling
that enhances integrin clustering.  This model is supported by the observation that clustering
increases the adhesion of LFA-1 (the αLβ2 integrin dimer) to ICAM-1 without increasing its
affinity (as measured by binding of soluble ICAM-1) (260).  Chemokines may specifically
increase affinity by a PI3K-independent pathway as well as enhancing PI3K-induced clustering
(256).  CXCL12, CCL19, and CCL21 each activate Wortmannin-sensitive LFA-1 binding to
ICAM-1 (256).  PI3K inhibitors also impair chemokine-triggered LFA-1 clustering in the cell
membrane and can completely block the formation of polarized cell “caps” (256).  Importantly,
PI3K activity is required for LFA-1-mediated arrest of cells on surfaces presenting low levels of
ICAM-1 under physiological flow strength.  When the affinity changes induced by chemokines
are examined by binding to soluble ligand, however, PI3K inhibitors exert no effect (256).  These
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results demonstrate that PI3K activity can enhance integrin functions downstream of the TCR and
chemokine receptors by mobilizing the movement of these molecules through the cell membrane.
Integrin expression, like that of chemokine receptors, is developmentally regulated.  Although
LFA-1 (αLβ2) is almost universally expressed on all thymocyte subsets (261), other integrins
display more restricted expression patterns.  The β1 integrin forms two principal dimers, with α4
and α5, which are referred to as VLA4 and VLA5, respectively.  Two additional dimers, α3β1 and
α6β1 are less common.  All β1 integrin dimers are expressed most highly in DN thymocytes and
are progressively downregulated during development (262, 263).  This expression pattern
correlates with the ability of thymocytes to bind the β1 ligand fibronectin: isolation of thymocytes
by adhesion to fibronectin enriches DN and DP subsets (264).  By contrast, SP thymocytes fail to
bind fibronectin-coated surfaces (264).  α6 can also dimerize with the β4 integrin.  The expression
of β4 resembles that of β1 dimers, but the β4 sequence is the most divergent of all integrins and
includes a very long (1000 amino acid), unique intracellular domain (265).  While this suggests
that β4 may exert unique signaling functions, this integrin is dispensable for thymocyte
development (266).  Other integrins are required for proper thymocyte development, however.
Tacβ1 is a trans-dominant inhibitor that blocks the activity of β1, β2, and β3 integrins.  Transgenic
Tacβ1 expression impairs thymocyte adhesion to fibronectin and consequently induces a partial
block at the DN to DP transition (262).  β1 activity is not absolutely required for thymocyte
development, however, since some SP do develop in these mice.  The various patterns of
expression of and requirement for integrins suggest that these molecules cooperate with
chemokine signals in the thymus.  Together they may ensure that thymocytes interact with
appropriate stromal cell partners at different stages of development.
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In fact, integrin and chemokine expression may be coupled in mature T lymphocytes.  Multiple
integrins (including α4, β 1, and β 2) are expressed at higher levels on CCR7- memory T cells
compared to those cells that are CCR7+ (267).  Intriguingly, this negative correlation matches the
coordinated expression of these molecules on thymocytes.  We examined the surface expression
of several integrins that are downregulated during thymocyte development.  Surface levels of α4,
β1, and β 4 are all reduced to intermediate levels in mature thymocytes subsets (Fig. 16C), in
agreement with previous results.  p110ABD thymocyte subsets express the same levels of these
integrins as NLC cells.  Taken in conjunction with the GPCR RT-PCR data, from this we
conclude that the developmental program of chemokine receptor and integrin expression is
unaltered by p110ABD expression.
Given the role of PI3K described in integrin activation, we sought to determine if p110ABD
expression altered the ability of thymocytes to bind to integrin ligands.  Since TCRβ- thymocytes
exhibit the highest integrin function, this could be a signal that is normally induced by chemokine
receptors in DN and DP cells to direct proper cell-cell associations required for efficient
development.  Inappropriate binding induced by p110ABD could thus retain mature thymocytes in
the thymic stroma.  Since β1 activity can be regulated by PI3K and Itk in T cells, and since β1
activity is normally downregulated during thymocyte development, we decided to examine β1
function in p110ABD thymocytes.  Furthermore, expression of the β1 ligand fibronectin is highest
in the medulla (268), and we observe proper SP thymocyte localization to this compartment (Fig.
13C).  We thus assessed the ability of thymocytes to adhere to retronectin-coated surfaces in
vitro.  Retronectin is a recombinant fragment of human fibronectin with a higher affinity for
integrins, and we observe that thymocytes bind better to surfaces coated with retronectin
compared to fibronectin.  We chose to use this ligand because the more robust response should
allow a greater dynamic range of detection.  Thymocytes were allowed to adhere to 96-well plates
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coated with varying concentrations.  After the removal of non-adherent cells, the efficiency of
adhesion was quantitated by staining adherent cells with crystal violet and measuring the OD at
595 nM.  We find that total thymocytes from NLC and p110ABD animals bind to retronectin with
the same dose-dependence (Fig. 16D).  However, these bound populations should largely be
composed of DN and DP cells.  We attempted to specifically assess the ability of purified SP
thymocytes to adhere to retronectin, but both NLC and p110ABD SP cells failed to bind.  The
crystal violet staining in these tests was below the level of reproducible detection (<0.02 OD),
and visual examination revealed virtually no bound cells.  Although PI3K can enhance the
function of β1 integrins in mature T cells, p110ABD-induced PI3K activity does not do so in SP
thymocytes.
4.5  How does p110ABD inhibit thymic exit?
Studies of p110γ-/- animals have revealed a critically important role for the class IB PI3K in the
chemotactic responses of multiple haematopoietic cells.  For example, in vitro chemotactic
responses of neutrophils and macrophages are decreased in p110γ-/- mice compared to wild-type
(175, 195).  Furthermore, p110γ-deficiency impairs inflammatory responses in vivo by disrupting
cell recruitment.  Peritoneal accumulation of neutrophils in response to challenge with Listeria
monocytogenes is halved in p110γ-/- mice compared to wild-type (175).  Recruitment of
neutrophils and macrophages in septic peritonitis responses is almost completely abrogated as
well, and p110γ-deficient animals are subsequently unable to clear peritoneal bacteria (195).
These effects correlate with the loss of Akt phosphorylation and activity in response to
chemokine treatment (175, 195).
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On the other hand, p110γ is largely dispensable in lymphocyte chemotaxis.  Thus far, a
thymocyte emigration defect has only been reported for one of the two p110γ-/- lines that have
been described (81, 175).  Even in those animals, thymic exit is merely impaired, not severely
compromised as in the PTX transgenic mice.  The migration of mature T cells was not explicitly
examined in p110γ-null animals and the chemotactic abilitites of these cells must be inferred.
p110γ-/- spleens contain half the number of CD4 T cells in p110γ+/- mice, but this may reflect the
reduced size and output of the thymii of these mice since peripheral lymph node numbers are the
same (155).  p110γ-/- mice do show a reduced footpad swelling reaction compared to p110γ+/-
when injected with LCMV (155).  CTLs purified from the spleens of LCMV-challenged p110γ-
deficient animals can lyse target cells in vitro, however, with the same efficiency as p110γ-
competent CTLs.  This suggests that the impaired footpad swelling response is due to inhibited T
cell migration to the site of infection rather than to a defect in T cell activation.  But these effects
are all minor compared to the severe defects in myeloid lineage chemotaxis.  PI3K usage by
chemokine receptors may therefore be distinct in different lineages.
While examination of p110γ-/- mice suggests that Class IA PI3Ks may also regulate lymphocyte
chemotaxis, genetic studies in animals have not demonstrated any essential functions.  This is
probably due to the compensatory activity of different subunits discussed above, since
thymocytes and T cells retain PI3K activity in mice lacking adaptor subunits.  The most
compelling evidence in vivo for the coordinate use of both class IA and IB PI3Ks in lymphocyte
chemotaxis is that of p110γ-/- mice expressing the activating p65PI3K transgene.  p65PI3K expression
is sufficient to restore normal thymic export in p110γ-null animals (81).  On the other hand, a
requirement for class IA PI3K has only been demonstrated in vitro with cell line clones.  Ward et
al. have established Tet-Off Jurkat clones in which the expression of dominant negative PI3K
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mutants can be regulated in a dose-dependent fashion (188).  ∆p85 expression can inhibit
CXCL12-induced chemotaxis of these cells, albeit to a smaller degree than a kinase-dead p110γ
mutant (188).  To date no dominant-negative class IA PI3K mice have been described.
Unfortunately, our own attempts to generate ∆p85 mice using the p1017 vector were
unsuccessful.  Although class IA PI3K clearly can influence chemotactic responses in
lymphocytes, a requirement for p85/p110 dimers remains to be conclusively proven.
Chemokine receptor triggering induces the activity of multiple PI3K effectors in lymphocytes,
but the roles of these signals are only slowly emerging.  The only T cell-specific chemokine
signal thus far described that does not induce Akt phosphorylation and activity is CCL20
(LARC/MIP3α) and its receptor CCR6 (269).  Although Akt activation is reported, the
importance or requirement for this PI3K effector has not been demonstrated in lymphocytes.
Rather the chemotactic requirement for Akt has been extensively studied in Dictyostelium, which
will be discussed in detail below.
Recent reports do suggest a chemotactic requirement for the T cell-specific and PI3K-dependent
Tec kinase Itk.  Calcium flux is rapidly activated in response to most T cell-activating
chemokines, including CXCL12, CCL19, CCL21, CCL25, CCL2 (MCP1), CCL5 (RANTES),
and IL8 (269-274).  Whether chemokine-induced increases of intracellular calcium are mediated
by Itk remains unclear, however.  CXCL12-induced Ca++ fluxes in T lymphoblasts are insensitive
to Wortmannin (184).  On the other hand, Jurkat Ca++ flux responses to CXCL12 are reduced by
expression of a kinase-dead Itk and by knockdown of Itk levels via siRNA (275).  The answer
may lie in the usage of multiple PLC isoforms by chemokine receptors.  For example, calcium
fluxes in NK cells stimulated with CXCL12 can be severely impaired by anti-PLCβ but not anti-
PLCγ antibodies (276).  Furthermore, chemokine-induced Ca++ influx is completely abrogated in
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neutrophils lacking both PLCβ2 and PLCβ3 isoforms (277).  Clearly the calcium flux responses
to chemokines, and potential roles for PI3K in their regulation, remain a poorly-understood field.
Itk may instead be required for cytoskeletal remodeling in response to chemokine receptor
triggering, rather than calcium influx.  This was first suggested by studies of CXCL12-induced
Jurkat polarization (275).  The polymerization of actin in response to CXCL12 is decreased in
Jurkat cells expressing a kinase-dead Itk mutant (275).  This effect can be traced to impaired
activation of Rac and Cdc42 when the GTP-binding of these factors is assessed (275).  These
results are complemented by the observation that Itk-null T cells and thymocytes exhibit impaired
migration to CXCL12 in vitro (278).  Furthermore, intranasal administration of CXCL12 fails to
recruit Itk-/- T cells in vivo, whereas wild-type cells rapidly accumulate in the lung (278).  Note
that PI3K- and Itk-mediated integrin activation appear to operate via integrin clustering in the
membrane (discussed above).  It is therefore tempting to speculate that Itk can contribute to
chemotaxis by cytoskeletal remodeling that enhances cell-cell contact and lymphocyte rolling.
Recent work has demonstrated that the CDM family of DOCK proteins can contribute to Rac
activation downstream of chemokine receptors.  DOCK2 deficiency specifically impairs Rac
activation by CXCL12, and lymphocyte migration is broadly defective in DOCK2-/- mice (279).
In particular, DOCK2-/- DP and SP thymocytes fail to migrate in response to CXCL12 and
CCL19, respectively (279).  The regulation of DOCK2 is still unknown, but may involve PI3K.
The related DOCK180 can bind PtdIns(3,4,5)P3 in vitro despite lacking a conventional PH
domain (280).  Although a direct association with PtdIns(3,4,5)P3 has not yet been described for
DOCK2, an indirect association may be mediated via ELMO proteins.  These scaffolding
molecules are evolutionarily conserved and contain a PH domain critical for cytoskeletal
reorganization (281).  Whether Itk and DOCK2 cooperate downstream of PI3K to mediate actin
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remodeling or whether they instead integrate separable GPCR signals remains to be determined.
How do we interpret the defect in p110ABD thymocyte egress in light of these results?  Given the
positive role of PI3K activity in chemotaxis discussed above, we should expect to observe
enhanced chemotactic responses in p110ABD thymocytes.  In order to make sense of our results,
we must consider work performed in the slime mold Dictyostelium by Firtel, et al..  Dictyostelium
cells are large, contain ample cytoplasm, have a dynamic cytoskeleton, and polarize and move
rapidly in response to chemoattractants: they thus provide an excellent system in which study and
visualize chemotaxis.  Furthermore, abundant evidence indicates that PI3K and Akt are critical
regulators of Dictyostelium chemotaxis (reviewed in (282)).  One of the most striking features of
chemotactic responses is the ability of cells to detect very minor differences in chemokine
concentration.  These shallow extracellular gradients are translated into steep intracellular
gradients of signaling molecules via the highly-controlled accumulation of PtdIns(3,4,5)P3 at the
leading edge of the cell (283).  This polarization requires the coordinated function of PI3K at the
leading edge and PTEN at the sides and rear (283).  Consequently Akt is rapidly and transiently
recruited to the leading edge of the cell (284).  In resting cells, an Akt PH domain-GFP fusion
protein is evenly distributed throughout the cytoplasm (284).  Upon stimulation with
chemoattractant, this protein translocates to the membrane within 3 seconds.  Maximal
accumulation is observed between 5 and 8 seconds, and translocation lasts no longer than 22
seconds.  This rapid return to the cytoplasm is referred to as “adaptation,” and it allows the cell to
essentially “reset.”  Chemotaxing cells are thus ready to reorient themselves at each chemotaxis
step.  This dynamic, highly localized accumulation of Akt appears to be required for cells to
respond to directional cues.  Expression of a myristoylated Akt results in uniform membrane
distribution that resembles that observed when cells are uniformly bathed in chemoattractant
(284).  Dictyostelium cells expressing myrAkt consequently migrate more slowly in response to
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chemoattractants (284).  Efficient chemotaxis thus requires strictly regulated membrane
localization of PI3K products and effectors.
We suspect that chemotaxis of mammalian cells also depends upon regulated spatial organization.
This notion is supported by visualization of p110γ-/- neutrophil migration in Zygmond chambers:
p110γ-null cells do not migrate in an oriented direction toward a chemoattractant but instead
move in all directions (285).  Furthermore, p110γ-/- neutrophils move at half the speed of wild-
type cells (285).  Lymphocytes also polarize in the presence of chemokine gradients.  Stimulation
of T lymphoblasts with CCL2 or CCL5 induces rapid clustering of CCR2 or CCR5, respectively,
that is oriented toward the chemokine (91).  T cells can specifically accumulate responding
chemokine receptors at the leading edge of cell movement.
We therefore propose that p110ABD expression impairs thymocyte migration by interfering with
the proper spatial organization of the cell membrane.  By uncoupling endogenous p110 from
adapter subunits, p110ABD induces unregulated accumulation of PtdIns(3,4,5)P3 in the cell
membrane.  This can be observed by the constitutive activation of Akt in p110ABD thymocytes.
We suspect that this results in uniform membrane distribution of active Akt that in turn inhibits
the ability of the thymocyte to properly respond to chemotactic signals.  This should be in
contrast to the effects of p65PI3K.  Since p65PI3K contains most of its protein-protein interaction
domains, it should still couple endogenous p110 subunits to stimulating receptors with
appropriate spatial organization.  Unfortunately, unlike Dictyostelium, thymocytes are extremely
small and contain very little cytoplasm.  We have attempted to visualize membrane distribution of
PtdIns(3,4,5)P3 by retrovirally introducing an Akt PH-GFP fusion protein.  But even at the
highest magnification we could not discriminate between membrane and cytoplasmic
localization.  Attempts to visualize p110ABD thymocyte movement and PH-GFP organization upon
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chemokine application are currently precluded by experimental constraints.
These results indicate that one must be careful when correlating the biochemical activity of
transgenes with the functional consequences.  Spatial organization of signaling molecules is
rapidly emerging as an important mode of regulation and must be considered.  We conclude by
proposing that p110ABD expression disrupts the ability of thymocytes to respond to emigration
signals in a properly oriented fashion.
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5. Conclusions
Class I PI3Ks are involved in both the regulation of mature T and B cell function and the
development of T and B cells (286, 287).  Studies using PI3K knockout mice have demonstrated
that alterations in both the adaptor (p85α, p55α p50α) (288, 289) and catalytic (p110δ) subunits
of PI3K (178), profoundly inhibit B cell development.  However these studies did not reveal any
defects in T cell development.  PI3K subunit redundancy, suggested by the residual PI3K activity
that can be observed in T cells in some of these knockout mice, may account for these results.
Alternatively, PI3K activity may not be as important for the development of  T cells as it is for B
cells.
We have used an alternative approach, transgenic expression of a gain-of-function mutant
(p110ABD) in thymocytes, to analyze the role of PI3K in immature DP and mature SP thymocytes.
The ability of our p110ABD construct to coimmunoprecipitate p85 and the decreased levels of
endogenous p110α (suggesting a shorter protein half-life) indicate that some fraction of
endogenous full-length p110α, and perhaps other p110 isoforms, are present as catalytically
active monomers in resting p110ABD thymocytes.  The constitutive activation of Akt in resting
p110ABD thymocytes agrees with this interpretation.  Furthermore, the activation levels achieved
with our construct are comparable to those induced in normal thymocytes by triggering of the
TCR/CD3 complex.  We also observe an improved ability to mobilize Ca++ in response to sub-
optimal concentrations of anti-CD3 antibodies.  We attribute this to a potentiation of TCR-
mediated Itk activation and subsequent PLCγ induction.
Expression of p110ABD results in an increase in the percentage and total numbers of mature SP T
cells in the thymus, clearly indicating that the levels of activity of PI3K can affect T cell
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development.  This phenotype could be the result of different processes in the DP compartment:
PI3K could improve DP survival, making it easier for the developing cells to express a good TCR
and be positively selected; it could improve positively selecting signals, rescuing cells whose
TCR react with very low affinity with self MHC+peptide; or it could inhibit negative selection,
allowing cells that would normally be deleted to mature.   The observed phenotype could also be
the consequence of changes in SP behavior, such as enhanced proliferation or a defect in
thymocyte emigration.  Any of these mechanisms would agree with the role of PI3K described in
other cell types and organisms.
An enhancement in survival would be consistent with the modification of DP survival reported in
gagPKB and Akt1-/- mice (179, 290).  However, in spite of elevated Akt activity, we did not find
changes in Bad phosphorylation or Bcl-XL levels in p110ABD thymocytes.  Nor did resting p110ABD
thymocytes exhibit increased NF-κB DNA-binding activity compared to NLC.  When we
specifically examined the survival of DP thymocytes in vitro in the absence of antigen or when
cultured with a corticosteroid, we found that NLC and p110ABD cells behave identically.  DP
survival was likewise unaffected by the expression of the activating transgene p65PI3K, in
agreement with our results (81).  Our observations suggest that Akt may play a minimal role
downstream of the TCR in thymocytes.
The increased numbers of mature T cells in the thymus of p110ABD mice could also be due to
improved positive selection.  To test this possibility we analyzed positive selection of the AND
Tg TCR in a weakly selecting background (H-2b/d).  Our results show that expression of p110ABD
dramatically improved selection in the H-2b/d background, almost restoring that observed in an
optimal selecting background, H-2b/b.  In order to discriminate emigration-related effects from
improved positive selection effects, we designed a BrdU tracking experiment to assess the daily
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generation of new SP thymocytes.  We found that p110ABD expression does specifically improve
positive selection, since a greater fraction of AND p110ABD SP thymocytes are freshly generated
from a labeled cohort: more BrdU+ cells differentiate to SP in AND p110ABD mice than in AND
animals.  By contrast, we were unable to detect any affects of p110ABD on negative selection,
either in vivo or using an in vitro deletion assay.
Positive selection is broadly impaired in Itk-/- and Rlk-/-Itk-/- mice and correlates with defective
Ca++ flux responses to TCR cross-linking (85-87, 235).  Since Rlk lacks a PH domain and is
PI3K-independent, we are confident that PI3K regulates positive selection via Itk and Ca++ influx
modulation.  The maximal Ca++ response is not increased by p110ABD expression, suggesting that
the effect of the transgene in vivo is more relevant for low affinity TCR-MHC interactions, those
that result in positive selection, than for the higher affinity interactions involved in negative
selection.  Since Ca++-dependent events, such as transcription of the Nur-77 family of
transcription factors (72), are critical for negative selection, and negative selection is also
disrupted by loss of Itk, the lack of effect of p110ABD may be due to a selective role for PI3K in
regulating Ca++ in response to low intensity stimuli.  It is also possible that the systems we used to
determine effects on negative selection are not sensitive enough to detect subtle differences, or
that the OT-I in vitro deletion cultures do not completely mimic negative selection in vivo.
However, overexpression in the thymus of low levels of constitutively active calcineurin, a
calcium regulated phosphatase, results in improved positive selection without alterations in
negative selection (73).  The role of calcineurin in the regulation of Nur77 remains controversial,
but there is evidence to suggest that calcineurin and Nur77 represent separate signaling pathways
downstream of Ca++ (238).
The findings on PI3K, Itk, calcineurin, and Nur77 are interesting to note in the context of the
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quantitative versus qualitative models for thymocyte selection.  From the reported roles of these
molecules, we can deduce that Ca++ influx constitutes a mechanism by which quantitative
differences in signal intensity can be converted into the activation of qualitatively different
pathways.  We postulate that low-intensity signals can activate positive selection pathways
(possibly calcineurin-related).  By contrast, high-intensity signals provoke pathways that mediate
negative selection which may include Nur77.  Thus, the conversion of negative selection to
positive selection observed in some Itk-/- Tg TCR mice is the consequence of impaired Ca++ flux.
According to this interpretation, p110ABD-induced PI3K activity is sufficient to lower the
threshold required for positive selection but not for negative selection.  Whether this mechanism
conforms to the threshold or duration model remains unclear, however.  Our observation that
p110ABD specifically enhances the primary Ca++ influx seems to suggest that the threshold model
most accurately represents the mechanism in play.  On the other hand, the primary Ca++ influx
appears normal Itk-/- and Rlk-/-Itk-/- thymocytes; rather the defect lies in a reduction of the
sustained levels of intracellular calcium, which argues instead for the duration model. It should be
noted, however, that Schaeffer et al. observe a slower decrease in intracellular Ca++ following the
initial peak in wild-type cells than we do.
Our results show that during T cell development PI3K contributes to the regulation of
intracellular calcium levels in response to low levels of TCR stimulation and improves the
efficiency of positive selection without affecting negative selection or survival.  These results,
together with experiments in the B cell system where PI3K mediates activation of Btk, which in
turn potentiates calcium fluxes, suggest that during development B and T cells share a common
signaling network to modulate intracellular calcium levels in response to low intensity signals
from their antigen receptor.
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The accumulation of mature SP CD3hi thymocytes that we observe in p110ABD mice appears to be
a compounded effect of enhanced positive selection and delayed thymic exit.  We observe
delayed colonization of peripheral tissues by p110ABD T cells in neonatal mice.  The delay is even
more striking in adoptive transfer recipients, in which significant numbers of wild-type derived T
cells appear in the periphery within 1 month but p110ABD-derived T cells are still completely
absent at 6 weeks.  Even at 4 months post-transfer, the p110ABD-derived cells have only achieved
the representation observed of wild-type cells at 1 month.  These results demonstrate that PI3K is
an important component of the signaling machinery that controls thymic exit.
Previous experiments suggested that an activating PI3K transgene (p65PI3K) increased the
emigration of CD4, but not CD8, thymocytes to the periphery (81), in direct contradiction of our
observations.  It is unclear how these results can be reconciled, although maybe the timing and/or
intensity of the effect on PI3K activity may account for the differences.  Thymocytes have been
shown to respond differently to low versus high concentrations of at least one chemokine,
CXCL12 (291), whose receptor (CXCR4) can activate Tec kinases in thymocytes and mature T
lymphocytes (275, 278).  Perhaps such a concentration-dependent “switch” also applies to the
PI3K activity induced by the emigration signal.  But we instead suspect that the difference lies in
the subcellular localization of PI3K catalytic activity in p110ABD versus p65PI3K cells.
Elegant studies using GFP fusion proteins have demonstrated that chemotactic responses of
Dictyostelium cells are highly dependent upon subcellular organization.  Chemotactic responses
are characterized by the rapid recruitment of Akt specifically to the leading edge of the cell.
Importantly, Akt is rapidly shuttled back to the cytoplasm.  It is suggested that this spatially
restricted accumulation and subsequent adaptation essentially resets the cell.  This is required for
the cell to properly respond to the next chemotactic signal.  Cells that express myrAkt exhibit
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constitutive Akt localization at the membrane on all surfaces and chemotactic responses are
subsequently slower.  These results suggest to us that p110ABD thymocytes are less responsive to
emigration signals because the disregulation of endogenous p110 recruitment to stimulating
receptors induces the constitutive and non-specific recruitment of Akt to the plasma membrane.
By contrast, p65PI3K can associate with endogenous p110 and contains all N-terminal protein-
protein association domains.  Constitutive PI3K activity should thus be restricted to appropriate
locations on the membrane of p65PI3K cells, thereby enhancing chemotactic responses.  While
these theories are all currently speculation, they provide a tempting model to explain the diverse
roles of seemingly similar transgenes.  Furthermore, they point to a previously unappreciated
aspect of control of signal transduction pathways.
In summary, we have demonstrated that PI3K can exert important functions during T lymphocyte
development that closely parallel those in B cell development.  PI3K is involved in signals from
both the TCR and GPCR in thymocytes, and can mediate differentiation and migration responses
to stimuli.
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Appendix:  Methods
Generation of p110ABD transgenic mice
The p110ABD construct, consisting of amino acids 1 through 109 of p110α, was obtained from
Julian Downward. The construct was cloned into the BamHI site of the p1017 vector (204), and
the NotI fragment purified and injected into (C57Bl/6 x DBA/2J)F1 zygote pronuclei. Founder
mice were identified by southern blotting of genomic DNA probed with a human growth
hormone fragment and subsequently backcrossed with C57Bl/6 mice (Jackson Laboratories, Bar
Harbor ME).  Subsequent progeny were genotyped by dot blot using the hGH probe or by PCR
with hGH-specific primers.  The generation of dnRas, Erksem, OT-1, HY, and AND transgenic
animals has been described previously (29, 35, 36, 46, 49).  Erksem mice were the kind gift of
Stephen M. Hedrick (UCSD). OT-1, HY, AND, Thy1.1, Ly5.1, and DBA/2J ice were all obtained
from Jackson Laboratories (Bar Harbor, ME)
Flow cytometric analyses
Phospho-S6 and phospho-Erk intracellular staining was performed as follows: 106 thymocytes
were stimulated in a volume of 300 µL.  At conclusion of stimulation, 40 µL of 16%
paraformaldehyde was added directly.  Samples were fixed for 10 minutes at 37°C, and then 1.8
mL of ice-cold methanol was rapidly added while votexing.  Cells were incubated on ice for 30
minutes then washed once with PBS containing 4% FCS. Incubation with antibodies in 100 µL of
PBS/FCS was performed for 20 minutes at room temperature (RT).  Cells were washed
thoroughly with vortexing to ensure removal of unbound antibody before analysis.  Primary
antibodies were obtained from Cell Signaling Technology (Beverly, MA): phospho-S6
Ribosomal protein (Ser235/236) cat. no. 2211; phospho-p44/42 MAPK (Thr202/Ty2204) E10
monoclonal cat. no. 9106.  phospho-S6 was detected with PE-conjugated Donkey anti-Rabbit IgG
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(Jackson ImmunoResearch cat. no. 711-116-152; West Grove, PA).  phospho-Erk was detected
by a two step amplification using biotin-conjugated Donkey anti-Mouse IgG (Jackson
ImmunoResearch cat. no. 715-066-151) and Stretpavidin-PE (BD Pharmingen; San Diego, CA).
For Ca++ flux analyses, primary thymocytes (106/mL) were labeled with Indo-1 (2µg/mL in HBSS
+ 1% FBS; Molecular Probes; Eugene, OR) for 30 minutes at 37°C. Cells were centrifuged and
stained with azide-free anti-CD8 FITC and anti-CD4 PE for 20 minutes at room temperature.
Samples were then diluted to 5 x 105 cells/mL and incubated for ≥ 5 minutes at 37°C before
analysis. Anti-CD3 antibody (2C11; BD Pharmingen) was added after 30 seconds, and Goat-anti-
Hamster IgG (Jackson ImmunoResearch cat. no. 127-005-099) added at 5 minutes. Maximal Ca++
flux was measured following stimulation with 1-2 µg/mL Ionomycin (Sigma cat. no. I0634; St.
Louis, MO), and calibrations were performed with the Calcium Calibration Buffer Kit #1
(Molecular Probes cat. no. C3008). The pre- and post-stimulation Ca++ levels corresponded with
those previously published as determined by comparison to the calibration standard (292).
Bcl-2 intracellular staining was performed according to manufacturer’s directions with the
Cytofix/Cytoperm kit (BD Pharmingen cat. no. 2075KK).  Briefly, freshly isolated thymocytes
(2x106) were suspended in 200 µL Cytofix/Cytoperm and incubated on ice for 30 minutes.  After
washing with PBS containing 1% FCS and 0.01% NaAzide, cells were resuspended in 80 µL
Perm/Wash and 20 µL anti-Bcl-2 FITC or isotype-matched control antibody (BD Pharmingen cat.
no. 1502KK).  Cells were incubated on ice 30 minutes, then washed twice with Perm/Wash and
resuspended in PBS/FCS/azide for analysis.
For simultaneous surface- and DNA content-staining, samples were first surface stained with
FITC- and PE-conjugated antibodies.  After thorough washing with PBS, cells were resuspended
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in 875 µL PBS containing 0.1% Na Azide.  Samples were vortexed immediately after addition of
125 µL 2%. Samples were fixed for 1 hour on ice, centrifuged, and all liquid aspirated.  Cells
were then permeabilized in 1 mL PBS containing 0.05% Tween 20 by incubation for 15 minutes
at 37°C.  Samples were washed thoroughly with PBS/azide and resuspended in 1mL 7AAD (25
µg/ml in PBS/azide; Molecular Probes cat. no. A1410).  Samples were incubated on ice at least
30 minutes, washed, and then analyzed within 2 hours.
All surface antibodies were obtained from BD Pharmingen or eBioscience (San Diego, CA) and
were used interchangably.  Analyses were performed using a Beckton-Dickinson FACSCalibur or
a Beckton-Dickinson FACScan, with the exception of Ca++ flux studies, which were performed
on a BD FACSVantage. Cell sorting for GPCR RT-PCR was also performed on the
FACSVantage.  All other cell sorting was performed on MACS magnetic columns (Miltenyi
Biotec, Auburn, CA), using biotinylated antibodies and Streptavidin Microbeads (Miltenyi
Biotec).  Analysis of flow cytometry data was performed using FlowJo (TreeStar Software,
Ashland, OR) or CellQuest (Beckton Dickinson)
Western blotting
Western blots were performed as described (45). The following primary antibodies were used:
rabbit anti-Bad C-20, mouse anti-Bcl-XL H-5, rabbit anti-p85α Z-8, rabbit anti-p110α H-201,
goat anti-p110α C-17, rabbit anti-p110δ H-219 (Santa Cruz Biotechnology, Santa Cruz, CA),
sheep anti-Bad phospho-Ser136 #06-799, rabbit anti-p85α #06-195 (Upstate), and rabbit anti-
MEK1/2 #9122 (Cell Signaling Technology).
Akt kinase assay
Akt  “in vitro“ kinase assays were performed using immunoprecipitates with an anti-Akt antibody
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(Stressgen cat. no. KAP-PK004E; Victoria, BC Canada) or sepharose-conjugated anti-Akt (N-19,
Santa Cruz Biotechnology).  2x107 cells were stimulated on plates either directly coated with anti-
CD3 antibodies (2C11) or coated with streptavidin (Pierce cat. no. 21122, Rockford, IL) and then
biotinylated anti-CD3 (BD Pharmingen).  After washing with cold PBS, stuimulated cells were
resuspended in 200 µL Buffer A (50 mM TrisCl pH 7.5, 50 mM NaF, 5 mM Na pyrophosphate,
1mM EDTA, 1 mM EGTA, 10 mM β-glycerophosphate, 1 mM Na3VO4, 0.1% (w/v) Triton X-
100, 0.1% (w/v) βME) containing 1 mM Mycrocystin-LR (BIOMOL cat. no. EI-193; Plymouth
Meeting, PA).  Samples were lysed for 5 minutes on ice, centrifuged at top speed 5 minutes, and
then Akt was immunoprecipitated from the supernatant.  Immunoprecipitates were washed twice
with Buffer A + 0.5 M NaCl and once with Assay Dilution Buffer (25 mM β-glycerophosphate
pH 7, 20 mM MOPS pH 7.2, 1 mM Na3VO4, 1 mM DTT).  To the aspirated pellet was added: 10
µL Assay Dilution Buffer, 10 µL myelin basic protein (0.1 µg/mL; GibcoBRL cat. no. 13228-
010; Gaithersburg, MD), and 10 µL [γ32P] ATP (1 µCi/µL in 75 mM MgCl2, 500 µM ATP).  The
reaction was performed for 15 minutes at 30°C and then stopped by the addition of SDS loading
buffer.  Samples were separated on a 12% SDS PAGE gel and either stained with Coomassie
Blue and dried or transferred to nitrocellulose.
NF-kB gel shift analyses
Nuclei were purified by first preparing cytoplasmic extracts: 107 thymocytes were resuspended in
100 µL CE buffer (10 mM HEPES-KOH pH 7.9, 60 mM KCl, 1 mM EDTA, 1 mM DTT, 1 mM
AEBSF) + 0.1% NP40.  Cells were lysed for 2 minutes on ice and then nuclei pelleted by
microcentrifugation at 4000 rpm.  Nuclei were lysed in 20 µL NE buffer (250 mM Tris pH 7.5,
60 mM KCl, 1 mM EDTA, 1 mM DTT, 1 mM AEBSF) by repeated freeze-thawing in dry
ice/95% EtOH and an ice water bath.  Lysates were cleared by centrifugation at 13000 rpm for 10
minutes, quantitated with the Micro BCA* Protein Assay kit (Pierce cat. no. 23235), and then
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adjusted to 1 µg/mL with NE buffer.  The Igκ hairpin probe fragment was a generous gift of
Alexander Hoffman and David Baltimore (CIT).  The probe was radiolabeled with T4 kinase, and
then probe (0.5 µL) and nuclear protein (2.5 µL) were incubated together for 30 minutes at RT in
Binding Buffer (10 mM TrisCl pH 7.5, 50 mM NaCl, 10% glycerol, 1% NP40, 1 mM EDTA, 0.1
mg/mL poly(dIdC) (Pharmacia cat. no. 27-7880-02; Piscataway, NJ)).  Samples were directly run
on a 5% acrylamide gel (30:0.8/TGE/5% glycerol) for 2 hours at 150V.  Gels were vaccuum-
dried and exposed to phosphoscreens.
Ribonuclease protection assay
RNA was extracted from thymocytes either with TRIzol reagent (Invitrogen; Carlsbad, CA) or
according to the single-step extraction protocol in Current Protocols in Molecular Biology (John
Wiley & Sons, Inc.).  All subsequent steps were performed according to manufacturer’s
instructions with the mAPO-2 probe template set (cat. no. 45354P), RiboQuant In Vitro
Transcription kit (cat. no. 45004K), and RiboQuant RPA kit (cat. no. 45014K), all from BD
Pharmingen.
In Vitro survival assays
106 thymocytes were aliquoted per well in a 96 well plate.  For antigen-independent assays, each
well was resuspended in 100 µL of DMEM complete with 10% FCS and βME.  Plates were
incubated at 37°C in 5% CO2 for varying times and then analysed by flow cytometry.  Viable DP
thymocytes were determined by forward and side scatter.  For Dexamethasone sensitivity assays,
each well was resuspended in 100 µL DMEM complete/FCS/βME containing 0, 10-9, 10-8, 10-7, or
10-6 M Dexamethasone ( Sigma cat. no. D1756).  Plates were incubated for 12 hours and then
analyzed by flow cytometry.  Viable DP thymocytes were determined by forward and side scatter
or Annexin V staining. Both methods gave identical results when tested in parallel.
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BrdU labeling experiments
BrdU (Sigma cat. no. B5002) was supplied one of two ways: for DP steady state analysis, BrdU
was provided continuously in drinking water at 0.8mg/ml until analysis; for pulse-chase analysis
of SP differentiation in AND H-2b/d animals, BrdU was administered in 2 intra-peritoneal
injections, each 1 mg in 200 µL PBS, 3 hours apart.  BrdU staining was performed in duplicate as
follows: cells were stained for surface antigens as usual, washed with PBS, and resuspended in
500 µL of 0.15 M NaCl. 1.2 mL of 95% EtOH at -20°C was added dropwise, and the cells
incubated for 30 minutes on ice. Following a wash with PBS, the cells were resuspended in 1 mL
of 1% paraformaldehyde/0.01% Tween-20 in PBS and incubated overnight at 4°C. The cells were
then centrifuged and directly resuspended in 1 mL of DNase I solution (50 Kunitz units/mL in
0.15 M NaCl, 4.2 mM MgCl2, 10 µM HCl; Sigma cat. no. D4527). After incubation for 30
minutes at 37°C, the samples were washed and stained with FITC anti-BrdU or isotype control
antibody (BD Pharmingen).
OT-1 deletion assays
In vitro deletion assays were performed with a protocol adapted from that described previously
(45). EL4 cells were irradiated with 3000 R and plated at 5 x 104 per well in round bottom 96 well
plates. The SIINFEKL peptide was diluted in DMEM and added to varying concentrations
ranging from 10-7 to 10-13 M. Duplicate samples of 106 OT-1 or OT-1 p110ABD thymocytes were
added per well to a final volume of 200 µL and incubated for 18 hours at 37°C. Samples were
then analyzed by flow cytometry as described for survival assays above.
Microscopy
Freshly-dissected thymic lobes were imbedded in Tissue-Tek OCT medium (Sakura Finetek cat.
no. 4583; Torrance, CA) and flash-frozen on dry ice.  Samples were stored at -80°C until
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sectioning.
For Giemsa staining, 10 µm sections were fixed for 5 minutes in methanol.  After rinsing
thoroughly in water to remove remaining OCT, slides were immersed in methanol for 3 minutes
twice.  Jenners stain (1 g in 500 mL methanol, diluted 1:1 with water) was applied for 15 minutes,
Giemsa stain (0.005% in water) for 5 minutes, and then slides were rinsed briefly in 95% and
100% ethanol.  Coverslips were mounted with Permount (Fisher).
For immunoflourescent staining, 8 µm sections were fixed in methanol for 3 minutes and then
washed in PBS with 1% FCS for 10 minutes 3x.  CD8-FITC and CD4-PE antibodies (BD
Pharmingen) were diluted in PBS/FCS and 100 µl applied to each section.  Slides were incubated
at RT in a humid chamber for 1 hour.  After washing twice in PBS/FCS and twice in PBS,
coverslips were mounted with Fluoromount-G (Southern Biotech cat. no. 0100-01; Birmingham,
AL).  Immunoflourescence was visualized using a Zeiss LSM Pascal inverted laser scanning
microscope in the Caltech Biological Imaging Center.  Data collection and analysis was
performed using the v3.2 SP 2 software.
Competitive adoptive bone marrow transfer
Bone marrow from C57Bl/6 Ly5.1 and p110ABD mice were depleted of CD3+ cells by MACS
(Miltenyi Biotech), mixed at a 1:1 ratio, and injected into recipient Thy1.1 mice that had been
lethally irradiated with 2 1200 R doses 3-4 hours apart. Mice were maintained on oral antibiotics
from 3 days prior to transfer until time of analysis, at which point animals were sacrificed and the
thymii, spleens, and mesenteric lymph nodes analyzed by flow cytometry.
Quantitative RT-PCR
Thymocyte subsets for RT-PCR were purified by FACS, and RNA prepared with the Ambion
RNAqueous kit (cat. no. 1912; Austin, TX) according to manufacturer’s instructions.
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Contaminating genomic DNA was removed with the Ambion DNA-free kit (cat. no. 1906) and
cDNA then synthesized with SuperScript II RT (Invitrogen cat. no. 18064-022).  Real-time PCR
was performed in triplicate with the SYBR Green system (Applied Biosystems cat. no. 4309155;
Foster City, CA) on a ABI Prism 7700 machine. The following primers were used:
GADPH forward (189) 5’-ACTCCACTCACGGCAAATTCA-3’
GADPH reverse (309) 5’-GCCTCACCCCATTTGATGTT-3’
S1P1 forward 5’-GTGTAGACCCAGAGTAATGCG-3’
S1P1 reverse 5’-AGCTTTTCCTTGGCTGGAGAG-3’
CCR7 forward 5’-CAGCCTTCCTCTCTCATTTCTACA-3’
CCR7 reverse 5’-ACCACCAGCACGTTTTTCCT-3’
CCR9 forward 5’-TGGTCAATGGATGTTCCAGA-3’
CCR9 reverse 5’-TGCACATGATGAGAAGCACA
CXCR4 forward 5’-GAAACTGCTGGCTGAAAAGG-3’
CXCR4 reverse 5’-CTGTCATCCCCCTGACTGAT-3’
(The CCR7 and S1P1 primers are those originally described in (114)).  Quantitation of mRNA
levels was performed according to manufacturer’s instructions using the formula 2-∆∆CT.
Transwell chemotaxis assays
In vitro chemotaxis assays were performed as previously described (114).  S1P was from Sigma.
CCL21 was obtained from R&D Systems (cat. no. 457-6C; Minneapolis, MN) or PeproTech (cat.
no. 250-13; Rocky Hill, NJ): both were used interchangeably.  Chemokine dilutions were
prepared in Migration Media (RPMI with 0.5% BSA, Pen/Strep, 10 mM HEPES).  600 µL was
aliquoted per well in a 24 well plate and the plate transferred to a 37°C incubator to let equilibrate
while preparing thymocytes.  Freshly isolated thymocytes were resuspended in Migration Media
at 107 per mL and allowed to pre-warm at 37°C for 10 minutes.  Transwell filters (6.5 mm
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Polycarbonate membrane, 5 µm pore size; Corning cat. no. 93421; Acton, MA) were inserted and
100 µL of thymocytes (106) aliquoted per chamber in duplicate.  Plates were then incubated at
37°C in 5% CO2.  To harvest migrants, the insert was removed by drawing it along the side of the
well to allow any medium on the underside to run back into the well.  Cells were then collected
and stained for flow cytometry analysis.  The number of migrants was determined by collecting
the entire sample during analysis.
Adhesion assays
Retronectin-coated plates were prepared by diluting retronectin in PBS pH 8, aliquoting 100 µL
per well, and incubating for 2 hours at 37°C.  Freshly isolated thymocytes were resuspended in
warm Tyrodes solution with 10% FCS (+ Na Pyruvate, Pen/Strep, Non-essential amino acids,
HEPES, 50 nM βME) at 107/mL.  100 µL/106 cells were aliquoted per well in triplicate and
allowed to bind for 45 minutes at 37°C in 5% CO2.  After PBS (100 µL) was added to each well,
the plate was inverted and gently centrifuged for 5 minutes at 100 g/700 rpm.  All remaining
liquid was aspirated and the adherent cells fixed in 70% EtOH for 20 mintes at RT.  The plate
was stained with 0.1% crystal violet in water for 5 minutes at RT and then rinsed briefly with
water to remove unbound stain.  Stained samples were resuspended in 0.2% Triton X-100 by
incubation at RT overnight and then quantitated by measuring the OD at 595 nM.  To specifically
assess SP adhesion, pooled thymocytes were depleted of HSAhi and NK1.1hi by MACS on LD+
columns (anti-NK1.1 was included to ensure removal of NKT cells which are HSA- (293)).
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